<SEC-DOCUMENT>0001104659-25-089778.txt : 20250915
<SEC-HEADER>0001104659-25-089778.hdr.sgml : 20250915
<ACCEPTANCE-DATETIME>20250915085052
ACCESSION NUMBER:		0001104659-25-089778
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250915
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250915
DATE AS OF CHANGE:		20250915

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HELIUS MEDICAL TECHNOLOGIES, INC.
		CENTRAL INDEX KEY:			0001610853
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				364787690
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38445
		FILM NUMBER:		251313320

	BUSINESS ADDRESS:	
		STREET 1:		642 NEWTOWN YARDLEY ROAD
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
		BUSINESS PHONE:		215-944-6100

	MAIL ADDRESS:	
		STREET 1:		642 NEWTOWN YARDLEY ROAD
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HELIUS MEDICAL TECHNOLOGIES, INC
		DATE OF NAME CHANGE:	20180517

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HELIUS MEDICAL TECHNOLOGIES, INC.
		DATE OF NAME CHANGE:	20140613
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2526081d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:hsdt="http://heliusmedical.com/20250915">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_hsdt_heliusmedical.com_20250915 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20250915_20250915 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001610853 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000004" name="dei:EntityCentralIndexKey">0001610853</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="hsdt-20250915.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-09-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610853</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-15</xbrli:startDate>
        <xbrli:endDate>2025-09-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>



<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b>&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_907_edei--DocumentType_c20250915__20250915_z1weKTxSWIYc"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)</b>&#8239;<b>of
the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):<span id="xdx_903_edei--DocumentPeriodEndDate_c20250915__20250915_zdPPcdtamhX7">
<ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">September 15, 2025</ix:nonNumeric></span></b></p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b><span id="xdx_902_edei--EntityRegistrantName_c20250915__20250915_zACvPQ7R90c9"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000011" name="dei:EntityRegistrantName">HELIUS MEDICAL TECHNOLOGIES, INC.</ix:nonNumeric>
</span></b></span></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding: 0.25pt; width: 33%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20250915__20250915_zyC99ITOvESe"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; width: 34%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityFileNumber_c20250915__20250915_zwklujuITx39"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000013" name="dei:EntityFileNumber">001-38445</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; width: 33%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20250915__20250915_zx2xYCgvMan"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000014" name="dei:EntityTaxIdentificationNumber">36-4787690</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other
jurisdiction</b></p></td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center"/><td style="padding: 0.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(IRS Employer</b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.25pt; text-align: center"><b>of incorporation)</b></td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission
    File Number)</b></span></td>
    <td style="padding: 0.25pt; text-align: center"><b>Identification No.)</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.25pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20250915__20250915_zrXZRqaky3Z4"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000015" name="dei:EntityAddressAddressLine1">642 Newtown Yardley Road</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20250915__20250915_zH4JJWzQdbNk"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite
    100</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20250915__20250915_z267NlC43Bqj"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000017" name="dei:EntityAddressCityOrTown">Newtown</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20250915__20250915_zRkZH7blamWl"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000018" name="dei:EntityAddressStateOrProvince">PA</ix:nonNumeric></span></b></p></td>
    <td style="padding: 0.25pt 0.25pt 0.25pt 7.45pt">&#160;</td>
    <td style="padding: 0.25pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressPostalZipCode_c20250915__20250915_zt3FnJ8YHgca"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000019" name="dei:EntityAddressPostalZipCode">18940</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.25pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="padding: 0.25pt 0.25pt 0.25pt 7.45pt">&#160;</td>
    <td style="padding: 0.25pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number,&#160;including
area code</b>: <b>(<span id="xdx_904_edei--CityAreaCode_c20250915__20250915_zCTdhwxf2t49"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000020" name="dei:CityAreaCode">215</ix:nonNumeric></span></b><b>) <span id="xdx_907_edei--LocalPhoneNumber_c20250915__20250915_zONDFF1yPAbf"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000021" name="dei:LocalPhoneNumber">944-6100</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address,
if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_904_edei--WrittenCommunications_c20250915__20250915_z72qKw4tEbQ5"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify">Written communications pursuant to Rule&#160;425 under the Securities
Act (17 CFR 230.425)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_902_edei--SolicitingMaterial_c20250915__20250915_zskcP9Yy7BE1"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange
Act (17 CFR 240.14a-12)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_903_edei--PreCommencementTenderOffer_c20250915__20250915_zqhBCILqKyta"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under
the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20250915__20250915_ziQd0UltLMOj"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under
the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 32%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading <br/>
Symbol(s)</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which&#8239;registered</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_90D_edei--Security12bTitle_c20250915__20250915_zgDB9o1qDjl6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000026" name="dei:Security12bTitle">Class&#160;A
    Common Stock, $0.001 par value</ix:nonNumeric></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_90F_edei--TradingSymbol_c20250915__20250915_z1v2Qd7Hdj15" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000027" name="dei:TradingSymbol">HSDT</ix:nonNumeric></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_904_edei--SecurityExchangeName_c20250915__20250915_zdRpcLQsafq4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule&#160;12b-2
of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Emerging growth
company </span><span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20250915__20250915_zsdYKXF3b33f"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><b>Item 1.01 Entry into a Material
Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529">On September&#160;15,
2025, Helius Medical Technologies,&#160;Inc. (the &#8220;Company&#8221;) entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;)
with Clear Street LLC (&#8220;Clear Street&#8221;) and Maxim Group LLC (&#8220;Maxim&#8221;) (each, an &#8220;Agent,&#8221; and, together,
the &#8220;Agents&#8221;), as co-sales agents, pursuant to which the Company may offer and sell shares of the Company&#8217;s Class&#160;A
common stock, par value $0.001 per share (the &#8220;Shares&#8221;) from time to time having an aggregate sales price of up to $92.8 million
(the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529">On September&#160;15,
2025, the Company filed a prospectus supplement with the Securities and Exchange Commission in connection with the Offering (the &#8220;Prospectus
Supplement&#8221;) under its existing shelf Registration Statement on Form&#160;S-3 (File&#160;No.&#160;333-270433)&#160;(the &#8220;Registration
Statement&#8221;) initially filed with the SEC on March&#160;9, 2023 and declared effective on May&#160;26, 2023, and the base prospectus
contained therein. Prior to the execution of the Sales Agreement, the Company terminated the sales agreement, dated as of June&#160;23,
2023, between the Company and Roth Capital Partners, LLC, in accordance with its terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529">Upon delivery
of a placement notice, and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Shares by any method that
is deemed an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4)&#160;promulgated under the Securities Act of 1933,
as amended, or any other method permitted by law, which may include negotiated transactions or block trades. The Company may sell the
Shares through the Agents in amounts and at times to be determined by the Company from time to time subject to the terms and conditions
of the Sales Agreement, but neither it nor the Agents have an obligation to sell any of the Shares in the Offering. No assurance can be
given that the Company will sell any Shares under the Sales Agreement, or, if it does, as to the price or the amount of Shares that it
sells or the dates when such sales will take place. The Company or the Agents may suspend or terminate the Offering upon notice to the
other parties and subject to other conditions. The Agents will use commercially reasonable efforts basis to effect the Sales consistent
with normal trading and sales practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529">The Company
has agreed to pay the Agents&#8217; commissions for their respective services in acting as agents in the sale of the Shares in the amount
of up to 3.00% of the aggregate gross proceeds it receives from each sale of its Shares pursuant to the Sales Agreement. The Company has
also agreed to provide the Agents with customary indemnification and contribution rights. In addition, the Company has agreed to reimburse
certain legal expenses incurred by the Agent in connection with execution of the Sales Agreement in an amount up to $75,000, in addition
to certain ongoing legal expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529">A copy of
the Sales Agreement is attached as Exhibit&#160;1.1 hereto and is incorporated herein by reference. The foregoing description of the material
terms of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529">Honigman LLP,
counsel to the Company, has issued an opinion relating to the validity of the Shares sold pursuant to the Offering. A copy of such legal
opinion, including the consent included therein, is attached as Exhibit&#160;5.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529">The Shares
are registered pursuant to the Registration Statement and the base prospectus contained therein, and offerings for the Shares will be
made only by means of the Prospectus Supplement. This Current Report on Form&#160;8-K&#160;shall not constitute an offer to sell or solicitation
of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the securities law of such state or jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529">At the special
meeting of stockholders of the Company held on May&#160;23, 2025 (the &#8220;Special Meeting&#8221;), the Company&#8217;s stockholders
approved an increase in the number of authorized shares of Common Stock to up to 800,000,000 shares, among other things. The Company intends
to file an amendment to the Company&#8217;s certificate of incorporation with the Secretary of State of the State of Delaware to increase
the number of shares of Common Stock authorized to 800,000,000 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 9%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01</b></span></td>
    <td style="width: 91%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="width: 97%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: white 1pt solid; text-align: center; width: 6%"><b>Exhibit</b> <b>No.</b></td>
<td style="width: 1%">&#160;</td>
<td style="border-bottom: white 1pt solid; width: 93%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><a href="tm2526081d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></a></td>
<td>&#160;</td>
<td><a href="tm2526081d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales Agreement, between the Company, <span>Clear Street LLC and Maxim Group LLC</span>, dated as of September&#160;15, 2025</span></a></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><a href="tm2526081d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
<td>&#160;</td>
<td><a href="tm2526081d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Honigman LLP </span></a></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><a href="tm2526081d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></a></td>
<td>&#160;</td>
<td><a href="tm2526081d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Honigman LLP (Contained in Exhibit&#160;5.1)</span></a></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104 </span></td>
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="vertical-align: top; padding-top: 0.75pt; padding-right: 1pt">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 1pt"><b>HELIUS MEDICAL TECHNOLOGIES,&#160;INC.</b> <b>&#160;</b></td></tr>
<tr>
<td style="padding-top: 0.75pt; padding-right: 1pt; width: 50%">&#160;</td>
<td style="vertical-align: bottom; width: 3%; padding-top: 0.75pt; padding-right: 1pt">&#160;</td>
<td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 1pt; width: 47%">&#160;</td></tr>
<tr>
<td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: September&#160;15, 2025</span></td>
<td style="vertical-align: top; padding-top: 0.75pt; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; padding-top: 0.75pt; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jeffrey S. Mathiesen</span></td></tr>
<tr>
<td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 1pt">&#160;</td>
<td style="padding-top: 0.75pt; padding-right: 1pt">&#160;</td>
<td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey S. Mathiesen</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding-top: 0.75pt; padding-right: 1pt">&#160;</td>
<td style="padding-top: 0.75pt; padding-right: 1pt">&#160;</td>
<td style="padding-top: 0.75pt; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer, Treasurer and Secretary</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 4; Options: NewSection Last; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LLoVBdmjY4o4ZQwRX6uLUtyakVbdPsm/tNsQQ0gI955cISZiQ2tdIcN5VWRwxLqplEMo8IaM5orekWx3Mfhd4F1bx8q44fyBCXkGPbOYSnnxwmB9aYtlDOFiFi5ncg5RFPuZ70XQ6wmZmy7ROK0qUKaEnKlhjU5xN344qpYM1d0QdUK2mkwM0TQc5Q/IMJJwoJd6Ez8sZFkigslQgdgwPRvvSluHpichrbD2cXak/x18AQeUSo4= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2526081d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>HELIUS MEDICAL TECHNOLOGIES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Class&nbsp;A Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($0.001 par value per share)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sales Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">September&nbsp;15, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clear Street LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4 World Trade Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">150 Greenwich Street, 45<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10007</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Maxim Group LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">300 Park Avenue, 16<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helius Medical Technologies,&nbsp;Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), confirms its agreement (this &ldquo;<U>Agreement</U>&rdquo;) with each of Clear
Street LLC (the &ldquo;<U>Clear Street</U>&rdquo;) and Maxim Group LLC (&ldquo;<U>Maxim</U>&rdquo; and each, an &ldquo;<U>Agent</U>&rdquo;
and together, the &ldquo;<U>Agents</U>&rdquo;), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">1.
</FONT><U>Issuance and Sale of Shares</U>. The Company agrees that, from time to time during the term of this Agreement, on the terms
and subject to the conditions set forth herein, it may issue and sell through or to the Agents, such number of shares (the &ldquo;<U>Placement
Shares</U>&rdquo;) of Class&nbsp;A common stock of the Company, $0.001 par value per share (the &ldquo;<U>Common Stock</U>&rdquo;) that
does not exceed the lesser of (a)&nbsp;the number or dollar amount of shares of Common Stock that may be sold pursuant to the Prospectus
Supplement (as defined below), (b)&nbsp;the number of authorized but unissued shares of Common Stock or (c)&nbsp;the number or dollar
amount of shares of Common Stock that would cause the Company or the offering of the Placement Shares to not satisfy the eligibility and
transaction requirements for use of Form&nbsp;S-3, including, if applicable, General Instruction I.B.6 of Registration Statement on Form&nbsp;S-3
(the lesser of (a), (b)&nbsp;and (c), the &ldquo;<U>Maximum Amount</U>&rdquo;). Notwithstanding anything to the contrary contained herein,
the parties hereto agree that compliance with the limitations set forth in this Section&nbsp;1 on the amount of Placement Shares issued
and sold under this Agreement shall be the sole responsibility of the Company and that Agents shall have no obligation in connection with
such compliance. The issuance and sale of Placement Shares through or to Agents will be effected pursuant to the Registration Statement
(as defined below) filed by the Company and declared effective by the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;),
although nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement to issue any Placement
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has filed, in
accordance with the provisions of the Securities Act of 1933, as amended, and the rules&nbsp;and regulations thereunder (the &ldquo;<U>Securities
Act</U><B>&rdquo;</B>), with the Commission a registration statement on Form&nbsp;S-3 (File No.&nbsp;333-270433), including a base prospectus,
relating to certain securities, including the Placement Shares to be issued from time to time by the Company, and which incorporates by
reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934,
as amended, and the rules&nbsp;and regulations thereunder (the &ldquo;<U>Exchange Act</U>&rdquo;). The Company has prepared a prospectus
supplement specifically relating to the Placement Shares (the &ldquo;<U>Prospectus Supplement</U>&rdquo;) to the base prospectus included
as part of such registration statement. The Company will furnish to the Agents, for use by the Agents, copies of the prospectus included
as part of such registration statement, as supplemented by the Prospectus Supplement, relating to the Placement Shares. Except where the
context otherwise requires, such registration statement, and any post-effective amendment thereto, including all documents filed as part
thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently
filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under the Securities Act or deemed to be a part of such registration statement
pursuant to Rule&nbsp;430B of the Securities Act, or any subsequent registration statement on Form&nbsp;S-3 filed pursuant to Rule&nbsp;415(a)(6)&nbsp;under
the Securities Act by the Company to cover any Placement Shares, is herein called the <B>&ldquo;</B><U>Registration Statement</U>.&rdquo;
The base prospectus, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented
by the Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most recently been filed by the Company
with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under the Securities Act, together with any then issued Issuer Free Writing Prospectus
(defined below), is herein called the &ldquo;<U>Prospectus</U>.&rdquo; Any reference herein to the Registration Statement, the Prospectus
or any amendment or supplement thereto, shall be deemed to refer to and include the documents incorporated or deemed to be incorporated
by reference therein, and any reference herein to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with
respect to the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof
of any document with the Commission deemed to be incorporated by reference therein (the &ldquo;<U>Incorporated Documents</U>&rdquo;).
For purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto
shall be deemed to include any copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval System,
or if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively, &ldquo;<U>EDGAR</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">2.
</FONT><U>Placements</U>. Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a &ldquo;<U>Placement</U>&rdquo;),
it will notify the Agents by email notice (or other method mutually agreed to in writing by the Parties) of the number or dollar value
of Placement Shares, the time period during which sales are requested to be made, any limitation on the number of Placement Shares that
may be sold in any one day and any minimum price below which sales may not be made (a &ldquo;<U>Placement Notice</U>&rdquo;), the form
of which is attached hereto as <U>Schedule 1</U>. The Placement Notice shall originate from any of the individuals from the Company set
forth on <U>Schedule 3</U> (with a copy to each of the other individuals from the Company listed on such schedule), and shall be addressed
to each of the individuals from the Agents set forth on <U>Schedule 3</U>, as such <U>Schedule 3</U> may be amended from time to time.
The Placement Notice shall be effective unless and until (i)&nbsp;the Agents decline to accept the terms contained therein for any reason,
in each of their sole discretion, (ii)&nbsp;the entire amount of the Placement Shares thereunder have been sold, (iii)&nbsp;the Company
suspends or terminates the Placement Notice or (iv)&nbsp;the Agreement has been terminated under the provisions of Section&nbsp;12. The
amount of any discount, commission or other compensation to be paid by the Company to the Agents in connection with the sale of the Placement
Shares shall be calculated in accordance with the terms set forth in <U>Schedule 2</U>. It is expressly acknowledged and agreed that neither
the Company nor the Agents will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until the
Company delivers a Placement Notice to the Agents and the Agents do not decline such Placement Notice pursuant to the terms set forth
above, and then only upon the terms specified therein and herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">3.
</FONT><U>Sale of Placement Shares by Agents</U>. Subject to the provisions of <U>Section&nbsp;5(a)</U>, the Agents, for the period specified
in the Placement Notice, will use commercially reasonable efforts consistent with their normal trading and sales practices and applicable
state and federal laws, rules&nbsp;and regulations and the rules&nbsp;of The Nasdaq Stock Market, LLC (the &ldquo;<U>Exchange</U>&rdquo;),
to sell the Placement Shares up to the amount specified, and otherwise in accordance with the terms of such Placement Notice. The Agents
will provide written confirmation to the Company no later than the opening of the Trading Day (as defined below) immediately following
the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day,
the compensation payable by the Company to the Agents pursuant to <U>Section&nbsp;2</U> with respect to such sales, and the Net Proceeds
(as defined below) payable to the Company, with an itemization of the deductions made by the Agents (as set forth in <U>Section&nbsp;5(b)</U>)
from the gross proceeds that it receives from such sales. Subject to the terms of the Placement Notice, the Agents may sell Placement
Shares (A)&nbsp;in privately negotiated transactions with the consent of the Company; (B)&nbsp;as block transactions; or (C)&nbsp;by any
other method permitted by law deemed to be &ldquo;at the market&rdquo; offering as defined in Rule&nbsp;415 of the Rules&nbsp;and Regulations,
including without limitation sales made through the Exchange or on any other existing trading market for the Common Stock. Notwithstanding
the foregoing, the Agents may, at any time and for any reason, suspend or discontinue sales of Placement Shares under any Placement Notice,
including, but not limited to, concerns regarding compliance with applicable law, market conditions, or reputational risk, by providing
notice to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">4.
</FONT><U>Suspension of Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&nbsp;</FONT>The
Company or the Agents may, upon notice to the other party in writing (including by email correspondence to each of the individuals of
the other party set forth on <U>Schedule 3</U>, if receipt of such correspondence is actually acknowledged by any of the individuals to
whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable facsimile transmission or email
correspondence to each of the individuals of the other party set forth on <U>Schedule 3</U>), suspend any sale of Placement Shares; <U>provided</U>,
<U>however</U>, that such suspension shall not affect or impair any party&rsquo;s obligations with respect to any Placement Shares sold
hereunder prior to the receipt of such notice. Each party agrees that no such notice under this Section&nbsp;4 shall be effective against
any other party unless it is made to one of the individuals named on <U>Schedule 3</U> hereto, as such <U>Schedule 3</U> may be amended
from time to time. While a suspension is in effect, any obligations under Sections 7(l), 7(m)&nbsp;and 7(n)&nbsp;with respect to delivery
of certifications, opinions or comfort letters to the Agents shall be waived (provided that, following such suspension, the Company shall
deliver such certification, opinion or comfort letter in accordance with Sections 7(l), 7(m)&nbsp;and 7(n)&nbsp;on or prior to the time
of delivery of a Placement Notice).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&nbsp;</FONT>Notwithstanding
any other provision of this Agreement, during any period in which the Company is in possession of material non-public information, the
Company and the Agents agree that (i)&nbsp;no sale of Placement Shares will take place, (ii)&nbsp;the Company shall not request the sale
of any Placement Shares, and (iii)&nbsp;the Agents shall not be obligated to sell or offer to sell any Placement Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">5.
</FONT><U>Sale and Delivery to the Agents; Settlement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&nbsp;</FONT><U>Sale
of Placement Shares</U><I>.</I> On the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, upon the Agents&rsquo; acceptance of the terms of a Placement Notice, and unless the sale of the Placement Shares described
therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement, the Agents, for the period
specified in the Placement Notice, will use their commercially reasonable efforts consistent with their normal trading and sales practices
to sell such Placement Shares up to the amount specified in such Placement Notice, and otherwise in accordance with the terms of such
Placement Notice. The Company acknowledges and agrees that (i)&nbsp;there can be no assurance that the Agents will be successful in selling
Placement Shares, (ii)&nbsp;the Agents will incur no liability or obligation to the Company or any other person or entity if they do not
sell Placement Shares for any reason other than a failure by the Agents to use their commercially reasonable efforts consistent with their
normal trading and sales practices and applicable law and regulations to sell such Placement Shares as required under this Agreement,
and (iii)&nbsp;the Agents shall be under no obligation to purchase Placement Shares on a principal basis pursuant to this Agreement, except
as otherwise agreed by the Agents and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&nbsp;</FONT><U>Settlement
of Placement Shares</U><I>.</I> Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares
will occur on the first (1st) Trading Day (or any such other settlement cycle as may be in effect pursuant to Rule&nbsp;15c6-1 under the
Exchange Act from time to time) following the date on which such sales are made (each, a &ldquo;<U>Settlement Date</U>&rdquo;). The amount
of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the &ldquo;<U>Net Proceeds</U>&rdquo;)
will be equal to the aggregate sales price received by the Agents, after deduction for (i)&nbsp;the Agents&rsquo; commission, discount
or other compensation for such sales payable by the Company pursuant to Section&nbsp;2 hereof, and (ii)&nbsp;any transaction fees imposed
by any clearing firm, execution broker, or governmental or self-regulatory organization in respect of such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&nbsp;</FONT><U>Delivery
of Placement Shares</U>. On each Settlement Date, against payment of the Net Proceeds, the Company will, or will cause its transfer agent
to, electronically transfer the Placement Shares being sold by crediting the Agents&rsquo; or their respective designee&rsquo;s account
(provided that the Agents shall have given the Company written notice of such designee prior to the Settlement Date) at The Depository
Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may be mutually agreed upon
by the parties hereto which in all cases shall be freely tradable, transferable, registered shares in good deliverable form. On each Settlement
Date, the Agents will deliver the related Net Proceeds in same day funds to an account designated by the Company on, or prior to, the
Settlement Date. The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation to deliver
Placement Shares on a Settlement Date (other than solely as a result of a failure by the Agents to provide instructions for delivery of
the applicable Placement Shares), the Company agrees that in addition to and in no way limiting the rights and obligations set forth in
Section&nbsp;10(a)&nbsp;hereto, it will (i)&nbsp;hold the Agents harmless against any loss, claim, damage, or reasonable and documented
expense (including reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company
or its transfer agent (if applicable) and (ii)&nbsp;pay to the Agents (without duplication) any commission, discount, or other compensation
to which it would otherwise have been entitled absent such default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&nbsp;</FONT><U>Limitations
on Offering Size</U><I>.</I> Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares if, after
giving effect to the sale of such Placement Shares, the aggregate gross sales proceeds of Placement Shares sold pursuant to this Agreement
would exceed the lesser of (A)&nbsp;together with all sales of Placement Shares under this Agreement, the Maximum Amount, (B)&nbsp;the
amount available for offer and sale under the Registration Statement and the Prospectus Supplement and (C)&nbsp;the amount authorized
from time to time to be issued and sold under this Agreement by the Company&rsquo;s board of directors, a duly authorized committee thereof
or a duly authorized executive committee, and notified to the Agents in writing. Under no circumstances shall the Company cause or request
the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum price authorized from time to time
by the Company&rsquo;s board of directors, duly authorized committee thereof or a duly authorized executive committee, and notified to
the Agents in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">6.
</FONT><U>Representations and Warranties of the Company</U>. Except as disclosed in the Registration Statement or Prospectus (including
the Incorporated Documents), the Company represents and warrants to, and agrees with the Agents that, as of the date of this Agreement
and as of each Applicable Time (as defined below), unless such representation, warranty or agreement specifies a different date or time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&nbsp;</FONT><U>Registration
Statement and Prospectus</U>. The Company and the transactions contemplated by this Agreement meet the requirements for and comply with
the conditions for the use of Form&nbsp;S-3 under the Securities Act. The Registration Statement has been filed with the Commission and
declared effective under the Securities Act. The Prospectus Supplement will name the Agents as the agents in the section entitled &ldquo;Plan
of Distribution.&rdquo; The Company has not received, and has no notice of, any order of the Commission preventing or suspending the use
of the Registration Statement, or threatening or instituting proceedings for that purpose. The Registration Statement and the offer and
sale of Placement Shares as contemplated hereby meet the requirements of Rule&nbsp;415 under the Securities Act and comply in all material
respects with said Rule. Any statutes, regulations, contracts or other documents that are required to be described in the Registration
Statement or the Prospectus or to be filed as exhibits to the Registration Statement have been so described or filed. Copies of the Registration
Statement, the Prospectus, and any such amendments or supplements and all documents incorporated by reference therein that were filed
with the Commission on or prior to the date of this Agreement have been delivered, or are available through EDGAR, to Agents and their
counsel. The Company has not distributed and, prior to the later to occur of each Settlement Date and completion of the distribution of
the Placement Shares, will not distribute any offering material in connection with the offering or sale of the Placement Shares other
than the Registration Statement and the Prospectus and any Issuer Free Writing Prospectus to which Agents have consented. Except as disclosed
in the Incorporated Documents, the Company has not, in the 12 months preceding the date hereof, received notice from the Exchange to the
effect that the Company is not in compliance with the listing or maintenance requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&nbsp;</FONT><U>No
Misstatement or Omission</U>. The Registration Statement, when it became effective, and the Prospectus, and any amendment or supplement
thereto, on the date of such Prospectus or amendment or supplement, conformed and will conform in all material respects with the requirements
of the Securities Act. At each Settlement Date, the Registration Statement and the Prospectus, as of such date, will conform in all material
respects with the requirements of the Securities Act. The Registration Statement, when it became effective, did not, and will not, contain
an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading. The Prospectus and any amendment or supplement thereto, on the date thereof and at each Applicable Time (defined
below), did not and will not include an untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading. Any Issuer Free Writing Prospectus, on the date thereof
and at each Applicable Time (defined below) and whether or not consented to in advance by either or both of the Agents, did not and will
not include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading. The foregoing shall not apply to statements in, or omissions from, any
such document made in reliance upon, and in conformity with, information furnished to the Company by Agents specifically for use in the
preparation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&nbsp;</FONT><U>Conformity
with Securities Act and Exchange Act</U>. The Registration Statement, the Prospectus, any Issuer Free Writing Prospectus or any amendment
or supplement thereto, and the Incorporated Documents, when such documents were or are filed with the Commission under the Securities
Act or the Exchange Act or became or become effective under the Securities Act, as the case may be, conformed and will conform in all
material respects with the requirements of the Securities Act and the Exchange Act, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&nbsp;</FONT><U>Financial
Information</U>. The financial statements of the Company included or incorporated by reference in the Registration Statement, the Prospectus
and the Issuer Free Writing Prospectuses, if any, together with the related notes and schedules, present fairly, in all material respects,
the financial position of the Company as of the dates indicated and the results of operations, cash flows and changes in stockholders&rsquo;
equity of the Company for the periods specified and have been prepared in compliance with the requirements of the Securities Act and Exchange
Act and in conformity with generally accepted accounting principles in the United States (&ldquo;<U>GAAP</U>&rdquo;) applied on a consistent
basis (except for (i)&nbsp;such adjustments to accounting standards and practices as are noted therein, (ii)&nbsp;in the case of unaudited
interim financial statements, to the extent such financial statements may not include footnotes required by GAAP or may be condensed or
summary statements and (iii)&nbsp;such adjustments which will not be material, either individually or in the aggregate) during the periods
involved; the other financial and statistical data with respect to the Company contained or incorporated by reference in the Registration
Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any, are accurately and fairly presented and prepared on a basis
consistent with the financial statements and books and records of the Company; there are no financial statements (historical or pro forma)
that are required to be included or incorporated by reference in the Registration Statement, or the Prospectus that are not included or
incorporated by reference as required; the Company does not have any material liabilities or obligations, direct or contingent (including
any off-balance sheet obligations), not described in the Registration Statement (excluding the exhibits thereto), and the Prospectus;
and all disclosures contained or incorporated by reference in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses,
if any, regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the rules&nbsp;and regulations of the Commission)
comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent
applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&nbsp;</FONT><U>Conformity
with EDGAR Filing</U>. The Prospectus delivered to the Agents for use in connection with the sale of the Placement Shares pursuant to
this Agreement will be identical to the versions of the Prospectus created to be transmitted to the Commission for filing via EDGAR, except
to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&nbsp;</FONT><U>Organization</U>.
The Company is duly organized, validly existing as a corporation and in good standing under the laws of its jurisdiction of organization.
The Company is, and will be, duly licensed or qualified as a foreign corporation for transaction of business and in good standing under
the laws of each other jurisdiction in which its ownership or lease of property or the conduct of its business requires such license or
qualification, and has all corporate power and authority necessary to own or hold its properties and to conduct its business as described
in the Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or
authority would not, individually or in the aggregate, have a material adverse effect on or affecting the assets, business, operations,
earnings, properties, condition (financial or otherwise), prospects, stockholders&rsquo; equity or results of operations of the Company
or prevent or materially interfere with consummation of the transactions contemplated hereby (a &ldquo;<U>Material Adverse Effect</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(g)&nbsp;</FONT><U>Subsidiaries</U>.
The Company owns directly or indirectly, all of the equity interests of its subsidiaries free and clear of any lien, charge, security
interest, encumbrance, right of first refusal or other restriction, and all the equity interests of its subsidiaries are validly issued
and are fully paid, non-assessable and free of preemptive and similar rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(h)&nbsp;</FONT><U>No
Violation or Default</U>. The Company is not (i)&nbsp;in violation of its charter or by-laws or similar organizational documents; (ii)&nbsp;in
default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance
or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement
or instrument to which the Company is a party or by which the Company is bound or to which any of the property or assets of the Company
is subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule&nbsp;or regulation of any court or arbitrator
or governmental or regulatory authority, except, in the case of each of clauses (ii)&nbsp;and (iii)&nbsp;above, for any such violation
or default that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. To the Company&rsquo;s
knowledge, no other party under any material contract or other agreement to which it is a party is in default in any respect thereunder
where such default would reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&nbsp;</FONT><U>No
Material Adverse Effect</U>. Subsequent to the respective dates as of which information is given in the Registration Statement, the Prospectus
and the Issuer Free Writing Prospectuses, if any, (including any document deemed incorporated by reference therein), there has not been
(i)&nbsp;any Material Adverse Effect, (ii)&nbsp;any transaction which is material to the Company, (iii)&nbsp;any obligation or liability,
direct or contingent (including any off-balance sheet obligations), incurred by the Company which is material to the Company, (iv)&nbsp;any
material change in the capital stock or outstanding long-term indebtedness (other than (A)&nbsp;the grant of additional awards under equity
incentive plans, (B)&nbsp;changes in the number of outstanding Common Stock due to the issuance of shares upon exercise or conversion
of securities exercisable for or convertible into Common Stock outstanding on the date hereof, (C)&nbsp;any repurchase of capital stock
of the Company, (D)&nbsp;as a result of the sale of Placement Shares, or (E)&nbsp;as publicly reported or announced), or (v)&nbsp;any
dividend or distribution of any kind declared, paid or made on the capital stock of the Company other than in each case above in the ordinary
course of business or as otherwise disclosed in the Registration Statement or Prospectus (including any document deemed incorporated by
reference therein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(j)&nbsp;</FONT><U>Capitalization</U>.
The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and non-assessable and, other
than as disclosed in the Registration Statement or the Prospectus, are not subject to any preemptive rights, rights of first refusal or
similar rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration Statement and the
Prospectus as of the dates referred to therein (other than the grant of additional options, restricted stock units or other equity compensation
granted under the Company&rsquo;s existing stock option plans, or changes in the number of outstanding shares of Common Stock of the Company
due to the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible into, Common Stock outstanding
on the date hereof) and such authorized capital stock conforms to the description thereof set forth in the Registration Statement and
the Prospectus. The description of the securities of the Company in the Registration Statement and the Prospectus is complete and accurate
in all material respects. Except as otherwise set forth in the Registration Statement, the Prospectus and the Company&rsquo;s public filings
on EDGAR, as of the date referred to therein, the Company does not have outstanding any options to purchase, or any rights or warrants
to subscribe for, or any securities or obligations convertible into, or exchangeable for, or any contracts or commitments to issue or
sell, any shares of capital stock or other securities. As disclosed in the Incorporated Documents, the Company intends to increase the
shares available for issuance under the Company&rsquo;s certificate of incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(k)&nbsp;</FONT><U>Authorization;
Enforceability</U>. The Company has full legal right, power and authority to enter into this Agreement and perform the transactions contemplated
hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a legal, valid and binding agreement of
the Company enforceable against the Company in accordance with its terms, except (i)&nbsp;to the extent that enforceability may be limited
by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo; rights generally and by general equitable
principles and (ii)&nbsp;the indemnification and contribution provisions of Section&nbsp;10 hereof may be limited by federal or state
securities laws and public policy considered in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(l)&nbsp;</FONT><U>Authorization
of Placement Shares</U>. The Placement Shares, when issued and delivered pursuant to the terms approved by the board of directors of the
Company or a duly authorized committee thereof, against payment therefor as provided herein, will be duly and validly authorized and issued
and fully paid and non-assessable, free and clear of any pledge, lien, encumbrance, security interest or other claim, including any statutory
or contractual preemptive rights, resale rights, rights of first refusal or other similar rights, and will be registered pursuant to Section&nbsp;12
of the Exchange Act. The Placement Shares, when issued, will conform in all material respects to the description thereof set forth in
or incorporated into the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(m)&nbsp;</FONT><U>No
Consents Required</U>. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or
governmental or regulatory authority having jurisdiction over the Company (or to which the Company is subject) is required for the execution,
delivery and performance by the Company of this Agreement, the issuance and sale by the Company of the Placement Shares, except for such
consents, approvals, authorizations, orders and registrations or qualifications as may be required under applicable state securities laws
or by the by-laws and rules&nbsp;of the Financial Industry Regulatory Authority (&ldquo;<U>FINRA</U>&rdquo;) or the Exchange in connection
with the sale of the Placement Shares by the Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(n)&nbsp;</FONT><U>No
Preferential Rights</U>. (i)&nbsp;No person, as such term is defined in Rule&nbsp;1-02 of Regulation S-X promulgated under the Securities
Act (each, a &ldquo;<U>Person</U>&rdquo;), has the right, contractual or otherwise, to cause the Company to issue or sell to such Person
any Common Stock or shares of any other capital stock or other securities of the Company (other than upon the exercise of outstanding
options, warrants or other rights to purchase Common Stock, or upon the exercise of equity awards that may be granted from time to time
under the Company&rsquo;s employee or director stock option or benefits plans, in each case as disclosed in the Registration Statement
or Prospectus), (ii)&nbsp;no Person has any preemptive rights, resale rights, rights of first refusal, or any other rights (whether pursuant
to a &ldquo;poison pill&rdquo; provision or otherwise) to purchase any Common Stock or shares of any other capital stock or other securities
of the Company, (iii)&nbsp;no Person has the right to act as an underwriter or as a financial advisor to the Company in connection with
the offer and sale of Common Stock in an &ldquo;at the market&rdquo; offering other than the Agents, and (iv)&nbsp;no Person has the right,
contractual or otherwise, to require the Company to register under the Securities Act any Common Stock or shares of any other capital
stock or other securities of the Company, or to include any such shares or other securities in the Registration Statement or the offering
contemplated thereby, whether as a result of the filing or effectiveness of the Registration Statement or the sale of the Placement Shares
as contemplated thereby or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(o)&nbsp;</FONT><U>Independent
Public Accountant</U>. Baker Tilly USA, LLP (the &ldquo;<U>Accountant</U>&rdquo;), whose report on the financial statements of the Company
is filed with the Commission as part of the Company&rsquo;s most recent Annual Report on Form&nbsp;10-K filed with the Commission and
incorporated into the Registration Statement and the Prospectus, are and, during the periods covered by their report, were an independent
registered public accounting firm with respect to the Company within the meaning of the Securities Act and the Public Company Accounting
Oversight Board (United States). To the Company&rsquo;s knowledge, the Accountant is not in violation of the auditor independence requirements
of the Sarbanes-Oxley Act of 2002 (the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;) with respect to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(p)&nbsp;</FONT><U>Enforceability
of Agreements</U>. All agreements between the Company and third parties expressly referenced in the Prospectus, to the extent that such
agreements are in effect as of the date of this Agreement (and subsequent dates on which this representation is made), are legal, valid
and binding obligations of the Company enforceable against the Company in accordance with their respective terms, except to the extent
that (i)&nbsp;enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo;
rights generally and by general equitable principles and (ii)&nbsp;the indemnification provisions of certain agreements may be limited
by federal or state securities laws or public policy considerations in respect thereof, and except for any unenforceability that, individually
or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(q)&nbsp;</FONT><U>No
Litigation</U>. There are no legal, governmental or regulatory actions, suits or proceedings pending, nor, to the Company&rsquo;s knowledge,
any legal, governmental or regulatory investigations, to which the Company is a party or to which any property of the Company is the subject
that, individually or in the aggregate, if determined adversely to the Company would reasonably be expected to have a Material Adverse
Effect or would reasonably be expected to materially and adversely affect the ability of the Company to perform its obligations under
this Agreement; to the Company&rsquo;s knowledge, no such actions, suits or proceedings are threatened or contemplated by any governmental
or regulatory authority or threatened by others that, individually or in the aggregate, if determined adversely to the Company, could
reasonably be expected to have a Material Adverse Effect; and (i)&nbsp;there are no current or pending legal, governmental or regulatory
investigations, actions, suits or proceedings that are required under the Securities Act to be described in the Prospectus that are not
so described; and (ii)&nbsp;there are no contracts or other documents that are required under the Securities Act to be filed as exhibits
to the Registration Statement that are not so filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(r)&nbsp;</FONT><U>Licenses
and Permits</U>. The Company possesses or has obtained, all licenses, certificates, consents, orders, approvals, permits and other authorizations
issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory
authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses
as described in the Registration Statement and the Prospectus (the &ldquo;<U>Permits</U>&rdquo;), except where the failure to possess,
obtain or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company
has not received written notice of any proceeding relating to revocation or modification of any such Permit or has any reason to believe
that such Permit will not be renewed in the ordinary course, except where the failure to obtain any such renewal would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(s)&nbsp;</FONT><U>No
Material Defaults</U>. The Company is not in default on any installment on indebtedness for borrowed money or on any rental on one or
more long-term leases, which defaults, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.
The Company has not filed a report pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act since the filing of its last
Annual Report on Form&nbsp;10-K, indicating that it (i)&nbsp;has failed to pay any dividend or sinking fund installment on preferred stock
or (ii)&nbsp;has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which
defaults, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(t)&nbsp;</FONT><U>S-3
Eligibility</U>. Since the latest of (i)&nbsp;the date the Registration Statement was declared effective and (ii)&nbsp;the filing of the
Company&rsquo;s most recent Annual Report on Form&nbsp;10-K, the aggregate market value of the voting and non-voting common equity held
by non-affiliates of the registrant was $75 million or more, in accordance with I.B.1 of Form&nbsp;S-3. The Company is not a shell company
(as defined in Rule&nbsp;405 under the Securities Act) and has not been a shell company for at least 36 calendar months previously and.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(u)&nbsp;</FONT><U>Certain
Market Activities</U>. Neither the Company nor, to the Company&rsquo;s knowledge, any of its directors, officers or controlling persons
has taken, directly or indirectly, any action designed, or that has constituted or would reasonably be expected to cause or result in,
under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of the Placement Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(v)&nbsp;</FONT><U>Broker/Dealer
Relationships</U>. Neither the Company nor any related entities (i)&nbsp;is required to register as a &ldquo;broker&rdquo; or &ldquo;dealer&rdquo;
in accordance with the provisions of the Exchange Act or (ii)&nbsp;directly or indirectly through one or more intermediaries, controls
or is a &ldquo;person associated with a member&rdquo; or &ldquo;associated person of a member&rdquo; (within the meaning set forth in
the FINRA Manual).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(w)&nbsp;</FONT><U>No
Reliance</U>. The Company has not relied upon the Agents or legal counsel for the Agents for any legal, tax or accounting advice in connection
with the offering and sale of the Placement Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(x)&nbsp;</FONT><U>Taxes</U>.
The Company has filed all federal, state, local and foreign tax returns which have been required to be filed and paid all taxes shown
thereon through the date hereof, to the extent that such taxes have become due and are not being contested in good faith. Except as otherwise
disclosed in or contemplated by the Registration Statement or the Prospectus, no tax deficiency has been determined adversely to the Company
which has had, or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. The Company has no
knowledge of any federal, state or other governmental tax deficiency, penalty or assessment which has been or might be asserted or threatened
against it which would reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(y)&nbsp;</FONT><U>Title
to Real and Personal Property</U>. The Company has good and valid title in fee simple to all items of real property and good and valid
title to all personal property described in the Registration Statement or Prospectus as being owned by it that are material to the business
of the Company, in each case free and clear of all liens, encumbrances and claims, except those that (i)&nbsp;do not materially interfere
with the use made and proposed to be made of such property by the Company or (ii)&nbsp;would not reasonably expected, individually or
in the aggregate, to have a Material Adverse Effect. Any real property described in the Registration Statement or Prospectus as being
leased by the Company is held by it under valid, existing and enforceable leases, except those that (A)&nbsp;do not materially interfere
with the use made or proposed to be made of such property by the Company or (B)&nbsp;would not be reasonably expected to have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(z)&nbsp;</FONT><U>Intellectual
Property</U>. The Company owns or possesses adequate enforceable rights to use all patents, patent applications, trademarks (both registered
and unregistered), service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses and know-how
(including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) (collectively,
the &ldquo;<U>Intellectual Property</U>&rdquo;), necessary for the conduct of its business as conducted as of the date hereof, except
to the extent that the failure to own or possess adequate rights to use such Intellectual Property would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect; the Company has not received any written notice of any claim of infringement
or conflict which asserted Intellectual Property rights of others, which infringement or conflict, if the subject of an unfavorable decision,
would result in a Material Adverse Effect; there are no pending, or to the Company&rsquo;s knowledge, threatened judicial proceedings
or interference proceedings against the Company challenging the Company&rsquo;s rights in or to or the validity of the scope of any of
the Company&rsquo;s patents, patent applications or proprietary information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(aa)
</FONT><U>Environmental Laws</U>. The Company (i)&nbsp;is in compliance with any and all applicable federal, state, local and foreign
laws, rules, regulations, decisions and orders relating to the protection of human health and safety, the environment or hazardous or
toxic substances or wastes, pollutants or contaminants (collectively, &ldquo;<U>Environmental Laws</U>&rdquo;); (ii)&nbsp;has received
and is in compliance with all permits, licenses or other approvals required of it under applicable Environmental Laws to conduct its businesses
as described in the Registration Statement and the Prospectus; and (iii)&nbsp;has not received notice of any actual or potential liability
for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants,
except, in the case of any of clauses (i), (ii)&nbsp;or (iii)&nbsp;above, for any such failure to comply or failure to receive required
permits, licenses, other approvals or liability as would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(bb)
</FONT><U>Disclosure Controls</U>. The Company maintains systems of internal controls designed to provide reasonable assurance that (i)&nbsp;transactions
are executed in accordance with management&rsquo;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets
is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv)&nbsp;the recorded accountability for
assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The
Company is not aware of any material weaknesses in its internal control over financial reporting (other than as set forth in the Prospectus).
Since the date of the latest audited financial statements of the Company included in the Prospectus, there has been no change in the Company&rsquo;s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s
internal control over financial reporting (other than as set forth in the Prospectus). The Company has established disclosure controls
and procedures (as defined in Exchange Act Rules&nbsp;13a-15 and 15d-15) for the Company and designed such disclosure controls and procedures
to ensure that material information relating to the Company is made known to the certifying officers by others within those entities,
particularly during the period in which the Company&rsquo;s Annual Report on Form&nbsp;10-K or Quarterly Report on Form&nbsp;10-Q, as
the case may be, is being prepared. The Company&rsquo;s certifying officers have evaluated the effectiveness of the Company&rsquo;s controls
and procedures as of a date within 90 days prior to the filing date of the Form&nbsp;10-K for the fiscal year most recently ended (such
date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its Form&nbsp;10-K for the fiscal year most recently ended the
conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as
of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the Company&rsquo;s internal controls (as
such term is defined in Item 307(b)&nbsp;of Regulation S-K under the Securities Act) or, to the Company&rsquo;s knowledge, in other factors
that could significantly affect the Company&rsquo;s internal controls. To the knowledge of the Company, the Company&rsquo;s &ldquo;internal
controls over financial reporting&rdquo; and &ldquo;disclosure controls and procedures&rdquo; are effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(cc)
</FONT><U>Sarbanes-Oxley</U>. The Company is not aware of any failure on the part of the Company or any of the Company&rsquo;s directors
or officers, in their capacities as such, to comply with any applicable provisions of the Sarbanes-Oxley Act and the applicable rules&nbsp;and
regulations promulgated thereunder in all material respects. Each of the principal executive officer and the principal financial officer
of the Company (or each former principal executive officer of the Company and each former principal financial officer of the Company as
applicable) has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules,
forms, statements and other documents required to be filed by it or furnished by it to the Commission during the past 12 months. For purposes
of the preceding sentence, &ldquo;principal executive officer&rdquo; and &ldquo;principal financial officer&rdquo; shall have the meanings
given to such terms in the Sarbanes-Oxley Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(dd)
</FONT><U>Finder&rsquo;s Fees</U>. The Company has not incurred any liability for any finder&rsquo;s fees, brokerage commissions or similar
payments in connection with the transactions herein contemplated, except as may otherwise exist with respect to Agents pursuant to this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ee)
</FONT><U>Labor Disputes</U>. No labor disturbance by or dispute with employees of the Company exists or, to the knowledge of the Company,
is threatened which would be reasonably likely to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ff)
</FONT><U>Investment Company Act</U>. The Company is not or after giving effect to the offering and sale of the Placement Shares and following
the use of proceeds thereof as disclosed in the Prospectus Supplement, will not be an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo;
by an &ldquo;investment company,&rdquo; as such terms are defined in the Investment Company Act of 1940, as amended (the &ldquo;<U>Investment
Company Act</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(gg)
</FONT><U>Operations</U>. The operations of the Company are and have been conducted at all times in compliance with applicable financial
record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering
statutes of all jurisdictions to which the Company is subject, the rules&nbsp;and regulations thereunder and any related or similar rules,
regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
except as would not have a Material Adverse Effect; and no action, suit or proceeding by or before any court or governmental agency, authority
or body or any arbitrator involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge of the Company,
threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(hh)
</FONT><U>Off-Balance Sheet Arrangements</U>. There are no transactions, arrangements and other relationships between and/or among the
Company, and/or, to the knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but not limited to,
any structural finance, special purpose or limited purpose entity (each, an &ldquo;<U>Off Balance Sheet Transaction</U>&rdquo;) that could
reasonably be expected to affect materially the Company&rsquo;s liquidity or the availability of or requirements for its capital resources,
including those Off Balance Sheet Transactions described in the Commission&rsquo;s Statement about Management&rsquo;s Discussion and Analysis
of Financial Conditions and Results of Operations (Release Nos. 33-8056; 34-45321; FR-61), required to be described in the Prospectus
which have not been described as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&nbsp;</FONT><U>Underwriter
Agreements</U>. Other than with respect to this Agreement, the Company is not a party to any agreement with an agent or underwriter for
any other &ldquo;at the market&rdquo; or continuous equity transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(jj)
</FONT><U>ERISA</U>. To the knowledge of the Company, each material employee benefit plan, within the meaning of Section&nbsp;3(3)&nbsp;of
the Employee Retirement Income Security Act of 1974, as amended (&ldquo;<U>ERISA</U>&rdquo;), that is maintained, administered or contributed
to by the Company or any of its affiliates for employees or former employees of the Company has been maintained in material compliance
with its terms and the requirements of any applicable statutes, orders, rules&nbsp;and regulations, including but not limited to ERISA
and the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;); no prohibited transaction, within the meaning of Section&nbsp;406
of ERISA or Section&nbsp;4975 of the Code, has occurred which would result in a material liability to the Company with respect to any
such plan excluding transactions effected pursuant to a statutory or administrative exemption; and for each such plan that is subject
to the funding rules&nbsp;of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no &ldquo;accumulated funding deficiency&rdquo;
as defined in Section&nbsp;412 of the Code has been incurred, whether or not waived, and the fair market value of the assets of each such
plan (excluding for these purposes accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan
determined using reasonable actuarial assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(kk)
</FONT><U>Forward Looking Statements</U>. No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and
Section&nbsp;21E of the Exchange Act) (a &ldquo;<U>Forward Looking Statement</U>&rdquo;) contained in the Registration Statement and the
Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. The Forward Looking
Statements incorporated by reference in the Registration Statement and the Prospectus from the Company&rsquo;s Annual Report on Form&nbsp;10-K
for the fiscal year most recently ended (i)&nbsp;are within the coverage of the safe harbor for forward looking statements set forth in
Section&nbsp;27A of the Securities Act, Rule&nbsp;175(b)&nbsp;under the Securities Act or Rule&nbsp;3b-6 under the Exchange Act, as applicable,
(ii)&nbsp;were made by the Company with a reasonable basis and in good faith and reflect the Company&rsquo;s good faith commercially reasonable
best estimate of the matters described therein, and (iii)&nbsp;have been prepared in accordance with Item 10 of Regulation S-K under the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ll)
</FONT><U>Agents Purchases</U>. The Company acknowledges and agrees that (a)&nbsp; Agents have informed the Company that the Agents may,
to the extent permitted under the Securities Act and the Exchange Act, purchase and sell Common Stock for their own account while this
Agreement is in effect, and (b)&nbsp;the Company shall not be deemed to have authorized or consented to any such purchases or sales by
the Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(mm)
</FONT><U>Margin Rules</U>. Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof
by the Company as described in the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors
of the Federal Reserve System or any other regulation of such Board of Governors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(nn)
</FONT><U>Insurance</U>. The Company carries, or is covered by, insurance in such amounts and covering such risks as the Company reasonably
believes is adequate for the conduct of its business and as is customary for companies engaged in similar businesses in similar industries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(oo)
</FONT><U>No Improper Practices</U>. (i)&nbsp;Neither the Company, nor to the Company&rsquo;s knowledge, any of its executive officers
has, in the past five years, made any unlawful contributions to any candidate for any political office (or failed fully to disclose any
contribution in violation of law) or made any contribution or other payment to any official of, or candidate for, any federal, state,
municipal, or foreign office or other person charged with similar public or quasi-public duty in violation of any law or of the character
required to be disclosed in the Prospectus; (ii)&nbsp;no relationship, direct or indirect, exists between or among the Company or, to
the Company&rsquo;s knowledge, any affiliate of the Company, on the one hand, and the directors, officers and stockholders of the Company,
that is required by the Securities Act to be described in the Registration Statement and the Prospectus that is not so described; (iii)&nbsp;no
relationship, direct or indirect, exists between or among the Company, or any affiliate of the Company, on the one hand, and the directors,
officers, stockholders or directors of the Company that is required by the rules&nbsp;of FINRA to be described in the Registration Statement
and the Prospectus that is not so described; (iv)&nbsp;there are no material outstanding loans or advances or material guarantees of indebtedness
by the Company to or for the benefit of any of its officers or directors or any of the members of the families of any of them; (v)&nbsp;the
Company has not offered, or caused any placement agent to offer, Common Stock to any person with the intent to influence unlawfully (A)&nbsp;a
customer or supplier of the Company to alter the customer&rsquo;s or supplier&rsquo;s level or type of business with the Company or (B)&nbsp;a
trade journalist or publication to write or publish favorable information about the Company or any of its products or services, and, (vi)&nbsp;neither
the Company nor, to the Company&rsquo;s knowledge, any employee or agent of the Company has made any payment of funds of the Company or
received or retained any funds in violation of any law, rule&nbsp;or regulation (including, without limitation, the Foreign Corrupt Practices
Act of 1977, which payment, receipt or retention of funds is of a character required to be disclosed in the Registration Statement or
the Prospectus).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(pp)
</FONT><U>Compliance with Applicable Laws</U>. The Company (A)&nbsp;to its knowledge, is and at all times has been in material compliance
with all statutes, rules&nbsp;and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use,
distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development,
manufactured or distributed by the Company (&ldquo;<U>Applicable Laws</U>&rdquo;), (B)&nbsp;has not received any Form&nbsp;483 from the
United States Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;), notice of adverse finding, warning letter, or other written correspondence
or notice from the FDA or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material
noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or
amendments thereto required by any such Applicable Laws (&ldquo;<U>Authorizations</U>&rdquo;), which would, individually or in the aggregate,
result in a Material Adverse Effect; (C)&nbsp;possesses all material Authorizations and such Authorizations are valid and in full force
and effect and the Company is not in material violation of any term of any such Authorizations; (D)&nbsp;has not received written notice
of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any other federal,
state, local or foreign governmental or regulatory authority or third party alleging that any Company product, operation or activity is
in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any other federal, state, local or
foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation
or proceeding against the Company; (E)&nbsp;has not received notice that the FDA or any other federal, state, local or foreign governmental
or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations
and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority is considering such
action; and (F)&nbsp;to its knowledge, has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations except where the failure
to file such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments would not result
in a Material Adverse Effect, and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements
or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(qq)
</FONT><U>Clinical Studies</U>. All clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are,
to the Company&rsquo;s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with
experimental protocols, procedures and controls generally used by qualified experts in the clinical trials of new drugs and biologics
as applied to comparable products to those being developed by the Company; the descriptions of the results of such clinical trials contained
in the Registration Statement and the Prospectus are accurate in all material respects, and the Company has no knowledge of any other
clinical trials, the results of which reasonably call into question the clinical trial results described or referred to in the Registration
Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written
notices or correspondence from the FDA or any other domestic or foreign governmental agency requiring the termination or suspension of
any clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the
results of which are referred to in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(rr)
</FONT><U>Status Under the Securities Act</U>. The Company was not and is not an ineligible issuer as defined in Rule&nbsp;405 under the
Securities Act at the times specified in Rules&nbsp;164 and 433 under the Securities Act in connection with the offering of the Placement
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ss)
</FONT><U>No Misstatement or Omission in an Issuer Free Writing Prospectus</U>. Each Issuer Free Writing Prospectus, as of its issue date
and as of each Applicable Time (as defined in <U>Section&nbsp;24</U> below), did not, does not and will not include any information that
conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any incorporated
document deemed to be a part thereof that has not been superseded or modified. The foregoing sentence does not apply to statements in
or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information furnished to the Company by
the Agents specifically for use therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(tt)
</FONT><U>No Conflicts</U>. Neither the execution of this Agreement, nor the issuance, offering or sale of the Placement Shares, nor the
consummation of any of the transactions contemplated herein and therein, nor the compliance by the Company with the terms and provisions
hereof and thereof will conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will constitute
a default under, or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance upon any property
or assets of the Company pursuant to the terms of any contract or other agreement to which the Company may be bound or to which any of
the property or assets of the Company is subject, except (i)&nbsp;such conflicts, breaches or defaults as may have been waived and (ii)&nbsp;such
conflicts, breaches and defaults that would not reasonably be expected to have a Material Adverse Effect; nor will such action result
(x)&nbsp;in any violation of the provisions of the organizational or governing documents of the Company, or (y)&nbsp;in any material violation
of the provisions of any statute or any order, rule&nbsp;or regulation applicable to the Company or of any court or of any federal, state
or other regulatory authority or other government body having jurisdiction over the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(uu)
</FONT><U>OFAC</U>. Neither the Company or any director, officer, agent, employee, affiliate or representative of the Company is a government,
individual or entity (in this paragraph (uu), &ldquo;<U>Person</U>&rdquo;) that is, or is owned or controlled by a Person that is, currently
subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;<U>OFAC</U>&rdquo;),
the United Nations Security Council (&ldquo;<U>UNSC</U>&rdquo;), the European Union (&ldquo;<U>EU</U>&rdquo;), Her Majesty&rsquo;s Treasury
(&ldquo;<U>HMT</U>&rdquo;), or other relevant sanctions authority (collectively, &ldquo;<U>Sanctions</U>&rdquo;), nor located, organized
or resident in a country or territory that is the subject of Sanctions; provided however, that for the purposes of this paragraph (uu),
no person shall be an affiliate of the Company solely by reason of owning less than a majority of any class of voting securities of the
Company. The Company will not directly or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing
the activities of any person currently subject to any U.S. sanctions administered by OFAC. The Company represents and covenants that,
except as detailed in the Prospectus, for the past 5 years, the Company has not knowingly engaged in, is not now knowingly engaged in,
and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing
or transaction is or was the subject of Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(vv)
</FONT><U>Stock Transfer Taxes</U>. On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required
to be paid in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully paid
or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ww)
</FONT><U>Cybersecurity</U>. To the knowledge of the Company and except as disclosed in the Company&rsquo;s public filings on EDGAR, (i)(x)&nbsp;there
has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any subsidiary&rsquo;s information technology
and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors
and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;)
and (y)&nbsp;the Company and the subsidiaries have not been notified of, and has no knowledge of any event or condition that would reasonably
be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii)&nbsp;the Company and the subsidiaries
are presently in compliance with all applicable laws or statutes and all judgments, orders, rules&nbsp;and regulations of any court or
arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security
of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification;
(iii)&nbsp;the Company and the subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect
its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and
(iv)&nbsp;the Company and the subsidiaries have implemented backup and disaster recovery technology consistent with industry standards
and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(xx)&nbsp;Crypto Assets and
Related Third-Party Arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company owns, directly or indirectly, and has good and valid title to all material Crypto Assets reflected in its financial statements
or otherwise held in connection with its business, free and clear of all liens, encumbrances, pledges, and security interests, other than
as disclosed in the Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
The Company holds Crypto Assets either (i)&nbsp;in digital wallets or cold storage under its sole control, or (ii)&nbsp;through custodial
arrangements with Anchorage (the &ldquo;<U>Custodian</U>&rdquo;), which is subject to a written agreement with the Company that includes
provisions addressing fiduciary duties (as applicable), asset segregation, loss and theft protections, incident reporting, and compliance
with applicable law. To the Company&rsquo;s knowledge, the Custodian is duly authorized or registered, as required, under applicable U.S.
federal or state law to perform digital asset custody services and complies in all material respects with applicable regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
The Company has authorized Pantera Capital Management LP (the &ldquo;<U>Asset Manager</U>&rdquo;) to manage or invest its Crypto Assets
pursuant to a Trading Advisory Agreement dated as of September&nbsp;15, 2025 (the &ldquo;<U>Asset Management Agreement</U>&rdquo;).&nbsp;
The Asset Management Agreement (x)&nbsp;does not transfer beneficial ownership of the Crypto Assets, (y)&nbsp;preserves the Company&rsquo;s
right to withdraw or liquidate such assets upon reasonable notice, and (z)&nbsp;requires periodic performance and risk reporting.&nbsp;
The Company conducts diligence on such service providers, monitors their activity, and maintains the ability to audit transactions and
balances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
The Company has implemented internal controls, security protocols, and oversight procedures designed to safeguard its Crypto Assets, manage
operational and custodial risks, and ensure accurate recordkeeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
The Company is in compliance with all applicable laws, rules, and regulations (including those administered by the SEC, Commodities Futures
Trading Commission, FinCEN, OFAC, and applicable state regulators) governing the holding, custody, transfer, and management of Crypto
Assets. To the Company&rsquo;s knowledge, no part of its Crypto Assets portfolio has been used in violation of applicable Money Laundering
Laws, counter-terrorist financing, or economic Sanctions laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
The Company has not received any written notice from any governmental or regulatory authority asserting that its Crypto Asset activities,
or those of any of the Custodian or the Asset Manager, are or have been in violation of law. The Company accounts for its Crypto Assets
and related arrangements in accordance with GAAP, including current accounting guidance, and its disclosures reflect the nature of custodial
relationships, risk of loss, and any arrangements that affect legal control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Agreement,
 &ldquo;<U>Crypto Assets</U>&rdquo; means digital assets that are issued or transferred using distributed ledger or blockchain technology,
including but not limited to cryptocurrencies (e.g., Bitcoin, Ethereum), stablecoins, and other fungible or non-fungible tokens held or
used by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(yy) <U>The Sales Agreement</U>.
This Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any certificate signed by an officer of the Company
and delivered to the Agents or to counsel for the Agents pursuant to or in connection with this Agreement shall be deemed to be a representation
and warranty by the Company, as applicable, to the Agents as to the matters set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000">7. </FONT><U>Covenants
of the Company</U>. The Company covenants and agrees with each Agent that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&nbsp;</FONT><U>Registration
Statement Amendments</U>. After the date of this Agreement and during any period in which a Prospectus relating to any Placement Shares
is required to be delivered by Agents under the Securities Act (including in circumstances where such requirement may be satisfied pursuant
to Rule&nbsp;172 under the Securities Act) (the &ldquo;<U>Prospectus Delivery Period</U>&rdquo;) (i)&nbsp;the Company will notify the
Agents promptly of the time when any subsequent amendment to the Registration Statement, other than documents incorporated by reference,
has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus has been filed and of any
request by the Commission for any amendment or supplement to the Registration Statement or Prospectus or for additional information; (ii)&nbsp;the
Company will prepare and file with the Commission, promptly upon the Agents&rsquo; reasonable request, any amendments or supplements to
the Registration Statement or Prospectus that, in such Agents&rsquo; reasonable opinion, may be necessary or advisable in connection with
the distribution of the Placement Shares by the Agents (provided, however, that the failure of the Agents to make such request shall not
relieve the Company of any obligation or liability hereunder, or affect the Agents&rsquo; right to rely on the representations and warranties
made by the Company in this Agreement and provided, further, that the only remedy the Agents shall have with respect to the failure to
make such filing shall be to cease making sales under this Agreement until such amendment or supplement is filed); (iii)&nbsp;the Company
will not file any amendment or supplement to the Registration Statement or Prospectus relating to the Placement Shares or a security convertible
into the Placement Shares unless a copy thereof has been submitted to Agents within a reasonable period of time before the filing and
the Agents have not objected thereto (provided, however, that (A)&nbsp;the failure of the Agents to make such objection shall not relieve
the Company of any obligation or liability hereunder, or affect the Agents&rsquo; right to rely on the representations and warranties
made by the Company in this Agreement and (B)&nbsp;the Company has no obligation to provide the Agents any advance copy of such filing
or to provide the Agents an opportunity to object to such filing if the filing does not name the Agents or does not relate to the transaction
herein provided; and provided, further, that the only remedy Agents shall have with respect to the failure to by the Company to obtain
such consent shall be to cease making sales under this Agreement) and the Company will furnish to the Agents at the time of filing thereof
a copy of any document that upon filing is deemed to be incorporated by reference into the Registration Statement or Prospectus, except
for those documents available via EDGAR; and (iv)&nbsp;the Company will cause each amendment or supplement to the Prospectus to be filed
with the Commission as required pursuant to the applicable paragraph of Rule&nbsp;424(b)&nbsp;of the Securities Act or, in the case of
any document to be incorporated therein by reference, to be filed with the Commission as required pursuant to the Exchange Act, within
the time period prescribed (the determination to file or not file any amendment or supplement with the Commission under this Section&nbsp;7(a),
based on the Company&rsquo;s reasonable opinion or reasonable objections, shall be made exclusively by the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&nbsp;</FONT><U>Notice
of Commission Stop Orders</U>. The Company will advise the Agents, promptly after it receives notice or obtains knowledge thereof, of
the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement, of
the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation or threatening
of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop
order or to obtain its withdrawal if such a stop order should be issued. The Company will advise the Agents promptly after it receives
any request by the Commission for any amendments to the Registration Statement or any amendment or supplements to the Prospectus or any
Issuer Free Writing Prospectus or for additional information related to the offering of the Placement Shares or for additional information
related to the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&nbsp;</FONT><U>Delivery
of Prospectus; Subsequent Changes</U>. During the Prospectus Delivery Period, the Company will comply with all requirements imposed upon
it by the Securities Act, as from time to time in force, and to file on or before their respective due dates all reports and any definitive
proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d)&nbsp;or
any other provision of or under the Exchange Act. If the Company has omitted any information from the Registration Statement pursuant
to Rule&nbsp;430A under the Securities Act, it will use its best efforts to comply with the provisions of and make all requisite filings
with the Commission pursuant to said Rule&nbsp;430A and to notify the Agents promptly of all such filings. If during the Prospectus Delivery
Period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material
fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading,
or if during the Prospectus Delivery Period it is necessary to amend or supplement the Registration Statement or Prospectus to comply
with the Securities Act, the Company will promptly notify Agents to suspend the offering of Placement Shares during such period and the
Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct such
statement or omission or effect such compliance; <U>provided</U>, <U>however</U>, that the Company may delay the filing of any amendment
or supplement, if in the judgment of the Company, it is in the best interests of the Company (provided that, if such amendment or supplement
is delayed, the Company shall not deliver a Placement Notice until such amendment or supplement has been filed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&nbsp;</FONT><U>Listing
of Placement Shares</U>. During the Prospectus Delivery Period, the Company will use its commercially reasonable efforts to cause the
Placement Shares to be listed on the Exchange and to qualify the Placement Shares for sale under the securities laws of such jurisdictions
as Agents reasonably designate and to continue such qualifications in effect so long as required for the distribution of the Placement
Shares; <U>provided</U>, <U>however</U>, that the Company shall not be required in connection therewith to qualify as a foreign corporation
or dealer in securities or file a general consent to service of process in any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&nbsp;</FONT><U>Delivery
of Registration Statement and Prospectus</U>. The Company will furnish to the Agents and their counsel (at the expense of the Company)
copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein) and all amendments and
supplements to the Registration Statement or Prospectus that are filed with the Commission during the Prospectus Delivery Period (including
all documents filed with the Commission during such period that are deemed to be incorporated by reference therein), in each case as soon
as reasonably practicable and in such quantities as the Agents may from time to time reasonably request and, at the Agents&rsquo; request,
will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may be made; <U>provided</U>,
<U>however</U>, that the Company shall not be required to furnish any document (other than the Prospectus) to the Agents to the extent
such document is available on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&nbsp;</FONT><U>Earnings
Statement</U>. The Company will make generally available to its security holders as soon as practicable, but in any event not later than
15 months after the end of the Company&rsquo;s current fiscal quarter, an earnings statement covering a 12-month period that satisfies
the provisions of Section&nbsp;11(a)&nbsp;and Rule&nbsp;158 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(g)&nbsp;</FONT><U>Use
of Proceeds</U>. The Company will use the Net Proceeds as described in the Prospectus in the section entitled &ldquo;Use of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(h)&nbsp;</FONT><U>Notice
of Other Sales</U>. Without the prior written consent of Agents, the Company will not, directly or indirectly, offer to sell, sell, contract
to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant to this Agreement)
or securities convertible into or exchangeable or exercisable for Common Stock, warrants or any rights to purchase or acquire, Common
Stock during the period beginning on the third Trading Date immediately prior to the date on which any Placement Notice is delivered to
Agents hereunder and ending on the second (2<FONT STYLE="font-size: 10pt"><SUP>nd</SUP></FONT>) Trading Day immediately following the
final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice (or, if the Placement Notice has been terminated
or suspended prior to the sale of all Placement Shares covered by a Placement Notice, the date of such suspension or termination); and
will not directly or indirectly in any other &ldquo;at the market&rdquo; or continuous equity transaction offer to sell, sell, contract
to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant to this Agreement)
or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire, Common Stock prior to
the later of the termination of this Agreement and the 60th day immediately following the final Settlement Date with respect to Placement
Shares sold pursuant to such Placement Notice; <U>provided</U>, <U>however</U>, that such restrictions will not be required in connection
with the Company&rsquo;s issuance or sale of (i)&nbsp;Common Stock, restricted stock, restricted stock units, options to purchase Common
Stock or Common Stock issuable upon the exercise of options, pursuant to any employee or director stock option or benefits plan, stock
ownership plan or dividend reinvestment plan (but not Common Stock subject to a waiver to exceed plan limits in its dividend reinvestment
plan) of the Company whether now in effect or hereafter implemented, (ii)&nbsp;Common Stock issuable upon conversion of securities or
the exercise of warrants, options or other rights in effect or outstanding, and disclosed in filings by the Company available on EDGAR
or otherwise in writing to the Agents or (iii)&nbsp;Common Stock, or securities convertible into or exercisable for Common Stock, as consideration
for mergers, acquisitions, other business combinations, or strategic alliances occurring after the date of this Agreement, which are not
issued for capital raising purposes. For the avoidance of doubt, nothing herein shall be construed to restrict the Company&rsquo;s ability,
or require the Company to provide notice to the Agents, to file a registration statement with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: a1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&nbsp;</FONT><U>Change
of Circumstances</U>. The Company will, at any time during the pendency of a Placement Notice advise the Agents promptly after it shall
have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material respect any
opinion, certificate, letter or other document required to be provided to the Agents pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(j)&nbsp;</FONT><U>Due
Diligence Cooperation</U>. The Company will cooperate with any reasonable due diligence review conducted by the Agents or their representatives
in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents
and senior corporate officers, during regular business hours and at the Company&rsquo;s principal offices, as the Agents may reasonably
request. The Company shall promptly notify the Agents of any material developments relating to the Company or the Placement Shares that
may affect the offering or the Agent&rsquo;s obligations hereunder, and shall provide the Agents with such information as the Agents may
reasonably request in connection with their ongoing due diligence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(k)&nbsp;</FONT><U>Required
Filings Relating to Placement of Placement Shares</U>. The Company agrees that on such dates as the Securities Act shall require, the
Company will (i)&nbsp;file a prospectus supplement with the Commission under the applicable paragraph of Rule&nbsp;424(b)&nbsp;under the
Securities Act (each and every filing under Rule&nbsp;424(b), a &ldquo;<U>Filing Date</U>&rdquo;), which prospectus supplement will set
forth, within the relevant period, the amount of Placement Shares sold through the Agents, the Net Proceeds to the Company and the compensation
payable by the Company to the Agents with respect to such Placement Shares, and (ii)&nbsp;deliver such number of copies of each such prospectus
supplement to each exchange or market on which such sales were effected as may be required by the rules&nbsp;or regulations of such exchange
or market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(l)&nbsp;</FONT><U>Representation
Dates; Certificate</U>. On the date of this Agreement and within five (5)&nbsp;trading days of each time the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(i)&nbsp;</FONT>files
the Prospectus relating to the Placement Shares or amends or supplements (other than a prospectus supplement relating solely to an offering
of securities other than the Placement Shares), the Registration Statement or the Prospectus relating to the Placement Shares by means
of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference into the Registration
Statement or the Prospectus relating to the Placement Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(ii)&nbsp;</FONT>files
an annual report on Form&nbsp;10-K under the Exchange Act (including any Form&nbsp;10-K/A containing amended financial information or
a material amendment to the previously filed Form&nbsp;10-K);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(iii)&nbsp;</FONT>files
a quarterly report on Form&nbsp;10-Q under the Exchange Act (including any Form&nbsp;10-Q/A containing amended financial information or
a material amendment to the previously filed Quarterly Report on Form&nbsp;10-Q); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(iv)&nbsp;</FONT>files
a current report on Form&nbsp;8-K containing amended financial information (other than information &ldquo;furnished&rdquo; pursuant to
Items 2.02 or 7.01 of Form&nbsp;8-K or to provide disclosure pursuant to Item 8.01 of Form&nbsp;8-K relating to the reclassification of
certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No.&nbsp;144) under the Exchange
Act; (Each date of filing of one or more of the documents referred to in clauses (i)&nbsp;through (iv)&nbsp;shall be a &ldquo;<U>Representation
Date</U>&rdquo;) the Company shall furnish the Agents (but in the case of clause (iv)&nbsp;above only if the Agents reasonably determine
that the information contained in such Form&nbsp;8-K is material) with a certificate, in the form attached hereto as <U>Exhibit&nbsp;7(l)</U>&nbsp;(the
 &ldquo;<U>Representation Date Certificate</U>&rdquo;); <U>provided</U>, <U>however</U>, that, if no Placement Notice is pending at such
Representation Date, then before the Company delivers a Placement Notice or the Agents sells any Placement Shares, the Company shall provide
the Agents with a Representation Date Certificate. The requirement to provide a Representation Date Certificate shall be waived for any
Representation Date occurring at a time at which no Placement Notice is pending, which waiver shall continue until the earlier to occur
of the date on which the Company delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Representation
Date) and the next occurring Representation Date; <U>provided</U>, <U>however</U>, that such waiver shall not apply for any Representation
Date on which the Company files its annual report on Form&nbsp;10-K. Notwithstanding the foregoing, if the Company subsequently decides
to sell Placement Shares following a Representation Date when the Company relied on such waiver and did not provide the Agents with a
Representation Date Certificate, then before the Company delivers the Placement Notice or the Agents sell any Placement Shares, the Company
shall provide the Agents with a Representation Date Certificate, dated the date of the Placement Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(m)&nbsp;</FONT><U>Legal
Opinion</U>. (1)&nbsp;On the date of this Agreement and (2)&nbsp;within five (5)&nbsp;Trading Days of each Representation Date, the Company
shall cause to be furnished to the Agents a written opinion and negative assurance letter of legal counsel to the Company (&ldquo;<U>Company
Counsel</U>&rdquo;), or other counsel satisfactory to the Agents, in form and substance satisfactory to Agents and their counsel. Thereafter,
within one (1)&nbsp;Trading Day of each Representation Date with respect to which the Company is obligated to deliver a Representation
Date Certificate for which no waiver is applicable, the Company shall cause to be furnished to the Agents a negative assurance letter
of Company Counsel in form and substance satisfactory to Agents and their counsel; <U>provided</U>, <U>however</U>, that if no Placement
Notice is pending at such Representation Date, then before the Company delivers a Placement Notice or the Agents sells any Placement Shares,
the Company shall provide the Agents with such negative assurance letter; provided, further, that in lieu of such negative assurance letter
for subsequent periodic filings under the Exchange Act, counsel may furnish the Agents with a letter (a &ldquo;<U>Reliance Letter</U>&rdquo;)
to the effect that the Agents may rely on a prior negative assurance letter delivered under this Section&nbsp;7(m)&nbsp;to the same extent
as if it were dated the date of such letter (except that statements in such prior negative assurance letter shall be deemed to relate
to the Registration Statement and the Prospectus as amended or supplemented as of the date of the Reliance Letter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(n)&nbsp;</FONT><U>Comfort
Letter</U>. (1)&nbsp;On the date of this Agreement and (2)&nbsp;within one (1)&nbsp;Trading Day of each Representation Date, with respect
to which the Company is obligated to deliver a certificate in the form attached hereto as <U>Exhibit&nbsp;7(l)</U>&nbsp;(other than a
Representation Date pursuant to Section&nbsp;7(l)(iii)), for which no waiver is applicable, the Company shall cause its independent accountants
to furnish the Agents letters (the &ldquo;<U>Comfort Letters</U>&rdquo;), dated on the date that the Comfort Letter is delivered, which
shall meet the requirements set forth in this Section&nbsp;7(n); <U>provided</U>, <U>however</U>, that, if no Placement Notice is pending
at such Representation Date, then before the Company delivers a Placement Notice or the Agents sells any Placement Shares, the Company
shall provide the Agents with the Comfort Letter; <U>provided</U>, <U>further</U>, that if reasonably requested by the Agents, the Company
shall cause a Comfort Letter to be furnished to the Agents within ten (10)&nbsp;Trading Days of the date of occurrence of any material
transaction or event, including the restatement of the Company&rsquo;s financial statements. The Comfort Letter from the Company&rsquo;s
independent accountants shall be in a form and substance satisfactory to the Agents, (i)&nbsp;confirming that they are an independent
public accounting firm within the meaning of the Securities Act and the Public Company Accounting Oversight Board (the &ldquo;<U>PCAOB</U>&rdquo;),
(ii)&nbsp;stating, as of such date, the conclusions and findings of such firm with respect to the financial information and other matters
ordinarily covered by accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters in connection with registered public offerings
(the first such letter, the &ldquo;<U>Initial Comfort Letter</U>&rdquo;) and (iii)&nbsp;updating the Initial Comfort Letter with any information
that would have been included in the Initial Comfort Letter had it been given on such date and modified as necessary to relate to the
Registration Statement and the Prospectus, as amended and supplemented to the date of such letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>(o)&nbsp;Chief Financial
Officer&rsquo;s Certificate</U>. If reasonably requested by the Agents, (1)&nbsp;on the date of this Agreement and (2)&nbsp;within five
(5)&nbsp;Trading Days of each Representation Date, with respect to which the Company is obligated to deliver a Representation Date Certificate
for which no waiver is applicable, the Company shall have delivered to the Agents a certificate executed by the Chief Financial Officer
of the Company, providing &ldquo;management comfort&rdquo; with respect to certain financial data included in the Prospectus, dated as
of such date, in form and substance satisfactory to the Agents (the &ldquo;<U>CFO Certificate</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>(p)&nbsp;Secretary&rsquo;s
Certificate</U>. (1)&nbsp;On the date of this Agreement and (2)&nbsp;within five (5)&nbsp;Trading Days of each Representation Date, with
respect to which the Company is obligated to deliver a Representation Date Certificate for which no waiver is applicable, the Company
shall have delivered to the Agents a certificate executed by the Secretary of the Company, dated as of such date, in form and substance
satisfactory to the Agents (the &ldquo;<U>Secretary&rsquo;s Certificate</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(q)&nbsp;</FONT><U>Market
Activities</U>. The Company will not, directly or indirectly, (i)&nbsp;take any action designed to cause or result in, or that constitutes
or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of Common Stock or (ii)&nbsp;sell, bid for, or purchase Common Stock in violation of Regulation M under the Exchange
Act, or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(r)&nbsp;</FONT><U>Investment
Company Act</U>. The Company will conduct its affairs in such a manner so as to reasonably ensure that it will not become, at any time
prior to the termination of this Agreement, an &ldquo;investment company,&rdquo; as such term is defined in the Investment Company Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(s)&nbsp;</FONT><U>No
Offer to Sell</U>. Other than an Issuer Free Writing Prospectus approved in advance by the Company and the Agents in its capacity as agents
hereunder, neither the Agents nor the Company (including its agents and representatives, other than Agents in their capacity as such)
will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule&nbsp;405 under the Securities Act),
required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Placement Shares hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(t)&nbsp;</FONT><U>Sarbanes-Oxley
Act</U>. The Company will maintain and keep accurate books and records reflecting its assets and maintain internal accounting controls
in a manner designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with GAAP and including those policies and procedures that (i)&nbsp;pertain to the maintenance
of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company, (ii)&nbsp;provide
reasonable assurance that transactions are recorded as necessary to permit the preparation of the Company&rsquo;s consolidated financial
statements in accordance with GAAP, (iii)&nbsp;that receipts and expenditures of the Company are being made only in accordance with management&rsquo;s
and the Company&rsquo;s directors&rsquo; authorization, and (iv)&nbsp;provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use or disposition of the Company&rsquo;s assets that could have a material effect on its financial statements.
The Company will use commercially reasonable efforts to maintain such controls and other procedures, including, without limitation, those
required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable regulations thereunder that are designed to ensure that
information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed,
summarized and reported, within the time periods specified in the Commission&rsquo;s rules&nbsp;and forms, including, without limitation,
controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits
under the Exchange Act is accumulated and communicated to the Company&rsquo;s management, including its principal executive officer and
principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure
and to ensure that material information relating to the Company is made known to it by others within the Company, particularly during
the period in which such periodic reports are being prepared.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">8.
</FONT><U>Payment of Expenses</U>. The Company will pay all expenses incident to the performance of its obligations under this Agreement,
including (i)&nbsp;the preparation, filing, including any fees required by the Commission, and printing of the Registration Statement
(including financial statements and exhibits) as originally filed and of each amendment and supplement thereto, in such number as the
Agents shall deem necessary, (ii)&nbsp;the printing and delivery to the Agents of this Agreement and such other documents as may be required
in connection with the offering, purchase, sale, issuance or delivery of the Placement Shares, (iii)&nbsp;the preparation, issuance and
delivery of the certificates, if any, for the Placement Shares to the Agents, including any stock or other transfer taxes and any capital
duties, stamp duties or other duties or taxes payable upon the sale, issuance or delivery of the Placement Shares to the Agents, (iv)&nbsp;the
fees and disbursements of the counsel, accountants and other advisors to the Company, (v)&nbsp;the reasonable out-of-pocket expenses of
Agents, including fees and disbursements of counsel to the Agents up to $75,000.00 (which amount shall include all fees and disbursements
of such counsel described in clause (ix)&nbsp;below) and reasonable quarterly disbursements of counsel to the Agents up to $15,000.00
per calendar quarter, (vi)&nbsp;the printing and delivery to the Agents of copies of any Permitted Issuer Free Writing Prospectus (defined
below) and the Prospectus and any amendments or supplements thereto in such number as the Agents shall deem necessary, (vii)&nbsp;the
preparation, printing and delivery to the Agents of copies of the blue sky survey and any Canadian &ldquo;wrapper&rdquo; and any supplements
thereto, in such number as the Agents shall deem necessary, (viii)&nbsp;the fees and expenses of the transfer agent and registrar for
the Common Stock, (ix)&nbsp;the fees and expenses incident to any review by FINRA of the terms of the sale of the Placement Shares, including
reasonable fees and expenses of counsel to the Agents, and (x)&nbsp;the fees and expenses incurred in connection with the listing of the
Placement Shares on the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">9.
</FONT><U>Conditions to Agent&rsquo;s Obligations</U>. The obligations of the Agents hereunder with respect to a Placement will be subject
to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by
the Company of its obligations hereunder, to the completion by the Agents of a due diligence review satisfactory to it in its reasonable
judgment, and to the continuing satisfaction (or waiver by the Agents in their sole discretion) of the following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&nbsp;</FONT><U>Registration
Statement Effective</U>. The Registration Statement shall have become effective and shall be available for the sale of all Placement Shares
contemplated to be issued by any Placement Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&nbsp;</FONT><U>No
Material Notices</U>. None of the following events shall have occurred and/or be continuing: (i)&nbsp;receipt by the Company of any request
for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness
of the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration Statement
or the Prospectus; (ii)&nbsp;the issuance by the Commission or any other federal or state governmental authority of any stop order suspending
the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii)&nbsp;receipt by the Company
of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares
for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv)&nbsp;the occurrence of any event
that makes any material statement made in the Registration Statement or the Prospectus or any material document incorporated or deemed
to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration
Statement, the Prospectus or documents so that, in the case of the Registration Statement, it will not contain any materially untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading
and, that in the case of the Prospectus, it will not contain any materially untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&nbsp;</FONT><U>No
Misstatement or Material Omission</U>. Agents shall not have advised the Company that the Registration Statement or Prospectus, or any
amendment or supplement thereto, contains an untrue statement of fact that, in the Agents&rsquo; reasonable opinion, is material, or omits
to state a fact that, in the Agents&rsquo; reasonable opinion, is material and is required to be stated therein or is necessary to make
the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&nbsp;</FONT><U>Material
Changes</U>. Except as contemplated in the Prospectus, or disclosed in the Company&rsquo;s public filings on EDGAR, there shall not have
been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect,
or any development that could reasonably be expected to cause a Material Adverse Effect, or a downgrading in or withdrawal of the rating
assigned to any of the Company&rsquo;s securities (other than asset backed securities) by any rating organization or a public announcement
by any rating organization that it has under surveillance or review its rating of any of the Company&rsquo;s securities (other than asset
backed securities), the effect of which, in the case of any such action by a rating organization described above, in the reasonable judgment
of the Agents (without relieving the Company of any obligation or liability it may otherwise have), is so material as to make it impracticable
or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&nbsp;</FONT><U>Legal
Opinion and Negative Assurance Letter</U>. The Agents shall have received the opinions and negative assurance letter of Company Counsel
required to be delivered pursuant Section&nbsp;7(m)&nbsp;on or before the date on which such delivery of such opinion and negative assurance
letter is required pursuant to Section&nbsp;7(m).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&nbsp;</FONT><U>[Reserved]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(g)&nbsp;</FONT><U>[Reserved]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(h)&nbsp;</FONT><U>Comfort
Letter</U>. The Agents shall have received the Comfort Letter required to be delivered pursuant Section&nbsp;7(n)&nbsp;on or before the
date on which such delivery of such Comfort Letter is required pursuant to Section&nbsp;7(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&nbsp;</FONT><U>Representation
Certificate</U>. The Agents shall have received the certificate required to be delivered pursuant to Section&nbsp;7(l)&nbsp;on or before
the date on which delivery of such certificate is required pursuant to Section&nbsp;7(l).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(j)&nbsp;</FONT><U>Secretary&rsquo;s
Certificate</U>. The Agents shall have received the Secretary&rsquo;s Certificate required to be delivered pursuant to Section&nbsp;7(p)&nbsp;on
or before the date on which delivery of such certificate is required pursuant to Section&nbsp;7(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(k)&nbsp;</FONT><U>CFO
Certificate</U>. The Agents shall have received the CFO Certificate required to be delivered pursuant to Section&nbsp;7(o)&nbsp;on or
before the date on which delivery of such certificate is required pursuant to Section&nbsp;7(o).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>(l)&nbsp;No Suspension</U>.
Trading in the Common Stock shall not have been suspended on the Exchange, and the Common Stock shall not have been delisted from the
Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(m)&nbsp;</FONT><U>Other
Materials</U>. On each date on which the Company is required to deliver a certificate pursuant to Section&nbsp;7(l), the Company shall
have furnished to the Agents such appropriate further information, certificates and documents as the Agents may reasonably request. All
such opinions, certificates, letters and other documents will be in compliance with the provisions hereof. The Company will furnish the
Agents with such conformed copies of such opinions, certificates, letters and other documents as the Agents shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(n)&nbsp;</FONT><U>Securities
Act Filings Made</U>. All filings with the Commission required by Rule&nbsp;424 under the Securities Act to have been filed prior to the
issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing by Rule&nbsp;424.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(o)&nbsp;</FONT><U>Approval
for Listing</U>. The Placement Shares shall either have been approved for listing quotation on the Exchange, subject only to notice of
issuance, or the Company shall have filed an application for listing quotation of the Placement Shares on the Exchange at, or prior to,
the issuance of any Placement Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(p)&nbsp;</FONT><U>No
Termination Event</U>. There shall not have occurred any event that would permit the Agents to terminate this Agreement pursuant to Section&nbsp;12(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">10.
</FONT><U>Indemnification and Contribution</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&nbsp;</FONT><U>Company
Indemnification</U>. The Company agrees to indemnify and hold harmless the Agents, their partners, members, directors, officers, employees
and agents and each person, if any, who controls the Agents within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20
of the Exchange Act as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(i)&nbsp;</FONT>against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based upon any untrue
statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), or the omission
or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading,
or arising out of any untrue statement or alleged untrue statement of a material fact included in any related Issuer Free Writing Prospectus
or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading (except to the extent
that such untrue statement or omission by the Company is made solely in reliance upon and conformity with written information relating
to the Agents furnished to the Company by the Agents expressly for use in the Registration Statement);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(ii)&nbsp;</FONT>against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate amount
paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened,
or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided
that (subject to Section&nbsp;10(d)&nbsp;below) any such settlement is effected with the written consent of the Agents, which consent
shall not unreasonably be delayed or withheld; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(iii)&nbsp;</FONT>against
any and all expense whatsoever, as incurred (including the reasonable fees and disbursements of counsel), reasonably incurred in investigating,
preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened,
or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent
that any such expense is not paid under (i)&nbsp;or (ii)&nbsp;above, <U>provided</U>, <U>however</U>, that this indemnity agreement shall
not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue
statement or omission made solely in reliance upon and in conformity with written information relating to the Agents furnished to the
Company by the Agents expressly for use in the Registration Statement (or any amendment thereto), or in any related Issuer Free Writing
Prospectus or the Prospectus (or any amendment or supplement thereto). For the avoidance of doubt, indemnification pursuant to Section&nbsp;10(a)(i)-(iii)&nbsp;hereunder
shall include reasonable and documented legal fees and expenses incurred in responding to or cooperating with regulatory investigation
or inquiry related to the offering, whether or not such investigation results in formal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&nbsp;</FONT><U>Agents
Indemnification</U>. Agents agree to indemnify and hold harmless the Company and its directors and each officer of the Company who signed
the Registration Statement, and each person, if any, who (i)&nbsp;controls the Company within the meaning of Section&nbsp;15 of the Securities
Act or Section&nbsp;20 of the Exchange Act or (ii)&nbsp;is controlled by or is under common control with the Company against any and all
loss, liability, claim, damage and expense described in the indemnity contained in Section&nbsp;10(a), as incurred, but only with respect
to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto)
or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with information relating to the Agents
and furnished to the Company in writing by the Agents expressly for use therein. Notwithstanding anything to the contrary herein, in no
event shall the Agents&rsquo; aggregate liability under this Agreement exceed the total compensation received by the Agents hereunder,
except in the case of gross negligence, willful misconduct, or fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&nbsp;</FONT><U>Procedure</U>.
Any party that proposes to assert the right to be indemnified under this Section&nbsp;10 will, promptly after receipt of notice of commencement
of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under this Section&nbsp;10,
notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served, but the omission so to
notify such indemnifying party will not relieve the indemnifying party from (i)&nbsp;any liability that it might have to any indemnified
party otherwise than under this Section&nbsp;10 and (ii)&nbsp;any liability that it may have to any indemnified party under the foregoing
provision of this Section&nbsp;10 unless, and only to the extent that, such omission results in the forfeiture of substantive rights or
defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies the indemnifying party
of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects by delivering written
notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified party, jointly
with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory to the
indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying
party will not be liable to the indemnified party for any legal or other expenses except as provided below and except for the reasonable
costs of investigation subsequently incurred by the indemnified party in connection with the defense. The indemnified party will have
the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense
of such indemnified party unless (1)&nbsp;the employment of counsel by the indemnified party has been authorized in writing by the indemnifying
party, (2)&nbsp;the indemnified party has reasonably concluded (based on written advice of counsel) that there may be legal defenses available
to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3)&nbsp;a conflict
or potential conflict exists (based on written advice of counsel to the indemnified party) between the indemnified party and the indemnifying
party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified
party) or (4)&nbsp;the indemnifying party has not in fact employed counsel to assume the defense of such action within a reasonable time
after receiving notice of the commencement of the action, in each of which cases the reasonable and documented fees, disbursements and
other charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party or
parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees,
disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction at any one time for all such
indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly after
the indemnifying party receives a written invoice relating to fees, disbursements and other charges in reasonable detail. An indemnifying
party will not, in any event, be liable for any settlement of any action or claim effected without its written consent. No indemnifying
party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment
in any pending or threatened claim, action or proceeding relating to the matters contemplated by this Section&nbsp;10 (whether or not
any indemnified party is a party thereto), unless such settlement, compromise or consent (1)&nbsp;includes an unconditional release of
each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (2)&nbsp;does not include
a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&nbsp;</FONT><U>Contribution</U>.
In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs
of this Section&nbsp;10 is applicable in accordance with its terms but for any reason is held to be unavailable from the Company or the
Agents, the Company and the Agents will contribute to the total losses, claims, liabilities, expenses and damages (including any investigative,
legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding
or any claim asserted, but after deducting any contribution received by the Company from persons other than the Agents, such as persons
who control the Company within the meaning of the Securities Act, officers of the Company who signed the Registration Statement and directors
of the Company, who also may be liable for contribution) to which the Company and the Agents may be subject in such proportion as shall
be appropriate to reflect the relative benefits received by the Company on the one hand and the Agents on the other hand. The relative
benefits received by the Company on the one hand and the Agents on the other hand shall be deemed to be in the same proportion as the
total net proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation
received by the Agents (before deducting expenses) from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation
provided by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion
as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company,
on the one hand, and the Agents, on the other hand, with respect to the statements or omission that resulted in such loss, claim, liability,
expense or damage, or action in respect thereof, as well as any other relevant equitable considerations with respect to such offering.
Such relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the Agents, the intent
of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The
Company and the Agents agree that it would not be just and equitable if contributions pursuant to this Section&nbsp;10(d)&nbsp;were to
be determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations
referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage,
or action in respect thereof, referred to above in this Section&nbsp;10(d)&nbsp;shall be deemed to include, for the purpose of this Section&nbsp;10(d),
any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action
or claim to the extent consistent with Section&nbsp;10(c)&nbsp;hereof. Notwithstanding the foregoing provisions of this Section&nbsp;10(d),
the Agents shall not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person
found guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) will be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section&nbsp;10(d), any person
who controls a party to this Agreement within the meaning of the Securities Act, and any officers, directors, partners, employees or agents
of the Agents, will have the same rights to contribution as that party, and each officer of the Company who signed the Registration Statement
will have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution,
promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be
made under this Section&nbsp;10(d), will notify any such party or parties from whom contribution may be sought, but the omission to so
notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they may have under
this Section&nbsp;10(d)&nbsp;except to the extent that the failure to so notify such other party materially prejudiced the substantive
rights or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant to the last sentence of
Section&nbsp;10(c)&nbsp;hereof, no party will be liable for contribution with respect to any action or claim settled without its written
consent if such consent is required pursuant to Section&nbsp;10(c)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">11.
</FONT><U>Additional Covenants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&nbsp;</FONT><U>Representations
and Covenants of the Agents</U>. The Agents each, respectively, represents and warrants that such Agent is duly registered as a broker-dealer
under FINRA, the Exchange Act and the applicable statutes and regulations of each state in which the Placement Shares will be offered
and sold, except such states in which such Agent is exempt from registration or such registration is not otherwise required. The Agents
shall continue, for the term of this Agreement, to be duly registered as a broker-dealer under FINRA, the Exchange Act and the applicable
statutes and regulations of each state in which the Placement Shares will be offered and sold, except such states in which such Agent
is exempt from registration or such registration is not otherwise required, during the term of this Agreement. The Agents shall comply
with all applicable law and regulations in connection with the transactions contemplated by this Agreement, including the issuance and
sale through the Agents of the Placement Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&nbsp;</FONT><U>Representations
and Agreements to Survive Delivery</U>. The indemnity and contribution agreements contained in Section&nbsp;10 of this Agreement and all
representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their respective
dates, regardless of (i)&nbsp;any investigation made by or on behalf of the Agents, any controlling persons, or the Company (or any of
their respective officers, directors or controlling persons), (ii)&nbsp;delivery and acceptance of the Placement Shares and payment therefor
or (iii)&nbsp;any termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">12.
</FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&nbsp;</FONT>The
Agents may terminate this Agreement, by written notice to the Company, as hereinafter specified at any time (1)&nbsp;if there has been,
since the time of execution of this Agreement or since the date as of which information is given in the Prospectus, any Material Adverse
Effect, or any development that is reasonably likely to have a Material Adverse Effect or, in the sole judgment of the Agents, is material
and adverse and makes it impractical or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement
Shares, (2)&nbsp;if there has occurred any material adverse change in the financial markets in the United States or the international
financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving
a prospective change in national or international political, financial or economic conditions, in each case the effect of which is such
as to make it, in the judgment of the Agents, impracticable or inadvisable to market the Placement Shares or to enforce contracts for
the sale of the Placement Shares, (3)&nbsp;if trading in the Common Stock has been suspended or limited by the Commission or the Exchange,
or if trading generally on the Exchange has been suspended or limited, or minimum prices for trading have been fixed on the Exchange,
(4)&nbsp;if any suspension of trading of any securities of the Company on any exchange or in the over-the-counter market shall have occurred
and be continuing, (5)&nbsp;if a major disruption of securities settlements or clearance services in the United States shall have occurred
and be continuing, or (6)&nbsp;if a banking moratorium has been declared by either U.S. Federal or New York authorities. Any such termination
shall be without liability of any party to any other party except that the provisions of Section&nbsp;8 (Expenses), Section&nbsp;10 (Indemnification),
Section&nbsp;11 (Survival of Representations), Section&nbsp;17 (Governing Law; Waiver of Jury Trial) and Section&nbsp;18 (Consent to Jurisdiction)
hereof shall remain in full force and effect notwithstanding such termination. If the Agents elect to terminate this Agreement as provided
in this Section&nbsp;12(a), the Agents shall provide the required notice as specified in Section&nbsp;13 (Notices).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&nbsp;</FONT>The
Company shall have the right, by giving five (5)&nbsp;days&rsquo; written notice as hereinafter specified, to terminate this Agreement
in its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any
other party except that the provisions of Section&nbsp;8, Section&nbsp;10, Section&nbsp;11, Section&nbsp;17 and Section&nbsp;18 hereof
shall remain in full force and effect notwithstanding such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&nbsp;</FONT>The
Agents shall have the right, by giving five (5)&nbsp;days&rsquo; written notice as hereinafter specified, to terminate this Agreement
in its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any
other party except that the provisions of Section&nbsp;8, Section&nbsp;10, Section&nbsp;11, Section&nbsp;17 and Section&nbsp;18 hereof
shall remain in full force and effect notwithstanding such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&nbsp;</FONT>Unless
earlier terminated pursuant to this Section&nbsp;12, this Agreement shall automatically terminate upon the issuance and sale of all of
the Placement Shares through the Agents on the terms and subject to the conditions set forth herein, provided that the provisions of Section&nbsp;8,
Section&nbsp;10, Section&nbsp;11, Section&nbsp;17 and Section&nbsp;18 hereof shall remain in full force and effect notwithstanding such
termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&nbsp;</FONT>This
Agreement shall remain in full force and effect unless terminated pursuant to Sections 12(a), (b), (c), or (d)&nbsp;above or otherwise
by mutual agreement of the parties; <U>provided</U>, <U>however</U>, that any such termination by mutual agreement shall in all cases
be deemed to provide that Section&nbsp;8, Section&nbsp;10, Section&nbsp;11, Section&nbsp;17 and Section&nbsp;18 shall remain in full force
and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&nbsp;</FONT>Any
termination of this Agreement shall be effective on the date specified in such notice of termination; <U>provided</U>, <U>however</U>,
that such termination shall not be effective until the close of business on the date of receipt of such notice by the Agents or the Company,
as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares
shall settle in accordance with the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(g)&nbsp;</FONT>Subject
to the additional limitations set forth in Section&nbsp;8 of this Agreement, in the event of termination of this Agreement prior to the
sale of any Placement Shares, the Agents shall be entitled to reimbursement of all reasonable and documented fees and expenses actually
incurred, including legal fees, regardless of whether such expenses are characterized as out-of-pocket.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">13.
</FONT><U>Notices</U>. All notices or other communications required or permitted to be given by any party to any other party pursuant
to the terms of this Agreement shall be in writing, unless otherwise specified, and if sent to the Agents, shall be delivered to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Clear Street LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">4 World Trade Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">150 Greenwich Street, 45<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">New York, NY 10007</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Maxim Group LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">300 Park Avenue, 16<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Attn: Robert Solomon</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">E-mail: Robert Solomon</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Winston&nbsp;&amp; Strawn LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">800 Capitol Street, Suite&nbsp;2400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Houston, TX 77002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Attn: Michael J. Blankenship</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">E-mail: mblankenship@winston.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and if to the Company, shall be delivered to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Helius Medical Technologies,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">642 Newtown Yardley Road, Suite&nbsp;100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Newtown, PA 18940</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Attn: Jeffrey Mathiesen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">E-mail: *********</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Honigman LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">650 Trade Centre Way Suite&nbsp;200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Kalamazoo, MI 49002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Attn: Phillip D. Torrence; N. Danny
Shulman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Email: PTorrence@honigman.com; NShulman@honigman.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each party to this Agreement
may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. Each
such notice or other communication shall be deemed given (i)&nbsp;when delivered personally or by verifiable facsimile transmission or
email correspondence (with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day or, if such day is not
a Business Day, on the next succeeding Business Day, (ii)&nbsp;on the next Business Day after timely delivery to a nationally-recognized
overnight courier and (iii)&nbsp;on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return
receipt requested, postage prepaid).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An electronic communication
(&ldquo;<U>Electronic Notice</U>&rdquo;) shall be deemed written notice for purposes of this Section&nbsp;13 if sent to the electronic
mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed received at the time the party sending
Electronic Notice receives verification of receipt by the receiving party. Any party receiving Electronic Notice may request and shall
be entitled to receive the notice on paper, in a nonelectronic form (&ldquo;<U>Nonelectronic Notic</U>e&rdquo;) which shall be sent to
the requesting party within ten (10)&nbsp;days of receipt of the written request for Nonelectronic Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">14.
</FONT><U>Successors and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the Company and the Agents and
their respective successors and the affiliates, controlling persons, officers and directors referred to in Section&nbsp;10 hereof. References
to any of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of such party. Nothing
in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors
and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement. Neither party may assign its rights or obligations under this Agreement without the prior written consent of the other
party; provided, however, that the Agents may assign their rights and obligations hereunder to an affiliate thereof without obtaining
the Company&rsquo;s consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">15.
</FONT><U>Adjustments for Stock Splits</U>. The parties acknowledge and agree that all share-related numbers contained in this Agreement
shall be adjusted to take into account any stock split, stock dividend or similar event effected with respect to the Placement Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">16.
</FONT><U>Entire Agreement; Amendment; Severability</U>. This Agreement (including all schedules and exhibits attached hereto and Placement
Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings,
both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof may
be amended except pursuant to a written instrument executed by the Company and the Agents. In the event that any one or more of the provisions
contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent
jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable,
and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision
was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof
shall be in accordance with the intent of the parties as reflected in this Agreement. Notwithstanding anything herein to the contrary,
the letter agreement, dated September&nbsp;15, 2025, by and between the Company and the Agents shall continue to be effective and the
terms therein shall continue to survive and be enforceable by the Agents in accordance with their terms, provided that, in the event of
a conflict between the terms of the letter agreement and this Agreement, the terms of this Agreement shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">17. </FONT><B><U>GOVERNING
LAW AND TIME; WAIVER OF JURY TRIAL</U>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE
OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. THE COMPANY
AND AGENTS EACH HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN
ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">18.
</FONT><B><U>CONSENT TO JURISDICTION</U>. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL
COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY
TRANSACTION CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM
THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT
FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS
AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN
RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE
GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE
PROCESS IN ANY MANNER PERMITTED BY LAW.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">19.
</FONT><U>Use of Information</U>. The Agents may not use any information gained in connection with this Agreement and the transactions
contemplated by this Agreement, including due diligence, to advise any party with respect to transactions not expressly approved by the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">20.
</FONT><U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be
made by facsimile transmission or email delivery of an executed Agreement as an attachment in .pdf format.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">21.
</FONT><U>Effect of Headings</U>. The section and Exhibit&nbsp;headings herein are for convenience only and shall not affect the construction
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">22.
</FONT><U>Free Writing Prospectuses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company represents, warrants
and agrees that, unless it obtains the prior consent of the Agents, which consent shall not be unreasonably withheld, conditioned or delayed,
and the Agents each represent, warrant and agree that, unless they obtain the prior consent of the Company, which consent shall not be
unreasonably withheld, conditioned or delayed, they have not made and will not make any offer relating to the Placement Shares that would
constitute an Issuer Free Writing Prospectus, or that would otherwise constitute a &ldquo;free writing prospectus,&rdquo; as defined in
Rule&nbsp;405, required to be filed with the Commission. The Company represents and warrants that it has treated and agrees that it will
treat each Issuer Free Writing Prospectus as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule&nbsp;433, and has complied
and will comply with the requirements of Rule&nbsp;433 applicable to any Issuer Free Writing Prospectus, including timely filing with
the Commission where required, legending and record keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">23.
</FONT><U>Absence of Fiduciary Relationship</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company acknowledges and
agrees that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&nbsp;</FONT>The
Agents are acting solely as agent in connection with the public offering of the Placement Shares and in connection with each transaction
contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory relationship between the Company
or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party, on the one hand,
and the Agents, on the other hand, has been or will be created in respect of any of the transactions contemplated by this Agreement, irrespective
of whether or not the Agents have advised or is advising the Company on other matters, and the Agents have no obligation to the Company
with respect to the transactions contemplated by this Agreement except the obligations expressly set forth in this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&nbsp;</FONT>it
is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated
by this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&nbsp;</FONT>the
Agents have not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this Agreement
and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&nbsp;</FONT>it
is aware that the Agents and their respective affiliates are engaged in a broad range of transactions which may involve interests that
differ from those of the Company and the Agents have no obligation to disclose such interests and transactions to the Company by virtue
of any fiduciary, advisory or agency relationship or otherwise; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&nbsp;</FONT>it
waives, to the fullest extent permitted by law, any claims it may have against the Agents for breach of fiduciary duty or alleged breach
of fiduciary duty in connection with the sale of Placement Shares under this Agreement and agrees that the Agents shall not have any liability
(whether direct or indirect, in contract, tort or otherwise) to it in respect of such a fiduciary duty claim or to any person asserting
a fiduciary duty claim on its behalf or in right of it or the Company, employees or creditors of Company, other than in respect of the
Agents&rsquo; obligations under this Agreement and to keep information provided by the Company to the Agent and the Agents&rsquo; counsel
confidential to the extent not otherwise publicly-available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">24.
</FONT><U>Definitions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this Agreement,
the following terms have the respective meanings set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Applicable Time</U>&rdquo;
means (i)&nbsp;each Representation Date, (ii)&nbsp;the time of each sale of any Placement Shares pursuant to this Agreement, and (iii)&nbsp;each
Settlement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>BHC Act Affiliate</U>&rdquo;
has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Covered Entity</U>&rdquo;
means any of the following: (i)&nbsp;a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12
C.F.R. &sect;&nbsp;252.82(b); (ii)&nbsp;a &ldquo;covered bank&rdquo; as that term is defined in, and interpreted in accordance with, 12
C.F.R. &sect;&nbsp;47.3(b); or (iii)&nbsp;a &ldquo;covered FSI&rdquo; as that term is defined in, and interpreted in accordance with,
12 C.F.R. &sect;&nbsp;382.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Default Right</U>&rdquo;
has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as
applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Issuer Free Writing
Prospectus</U>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule&nbsp;433, which has been consented to
in advance in writing by the Agent and which relates to the Placement Shares that (1)&nbsp;is required to be filed with the Commission
by the Company, (2)&nbsp;is a &ldquo;road show&rdquo; that is a &ldquo;written communication&rdquo; within the meaning of Rule&nbsp;433(d)(8)(i)&nbsp;whether
or not required to be filed with the Commission, or (3)&nbsp;is exempt from filing pursuant to Rule&nbsp;433(d)(5)(i)&nbsp;because it
contains a description of the Placement Shares or of the offering that does not reflect the final terms, in each case in the form filed
or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant
to Rule&nbsp;433(g)&nbsp;under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;172</U>,&rdquo;
 &ldquo;<U>Rule&nbsp;405</U>,&rdquo; &ldquo;<U>Rule&nbsp;415</U>,&rdquo; &ldquo;<U>Rule&nbsp;424</U>,&rdquo; &ldquo;<U>Rule&nbsp;424(b)</U>,&rdquo;
 &ldquo;<U>Rule&nbsp;430B</U>,&rdquo; and &ldquo;<U>Rule&nbsp;433</U>&rdquo; refer to such rules&nbsp;under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means any day on which shares of Common Stock are purchased and sold on the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>U.S. Special Resolution
Regime</U>&rdquo; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title
II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">25.</TD><TD STYLE="text-align: justify"><U>Recognition of the U.S. Special Resolution Regimes</U><I>.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that either or both of the Agents is a Covered Entity and becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from the Agent(s)&nbsp;of this Agreement, and any interest and obligation in or under this Agreement, will be effective to
the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and
obligation, were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that either or both of the Agents is a Covered Entity and the Agent(s)&nbsp;or a BHC Act Affiliate of the Agent(s)&nbsp;becomes
subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against the
Agent(s)&nbsp;are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution
Regime if this Agreement were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this Agreement
to financial statements and schedules and other information that is &ldquo;contained,&rdquo; &ldquo;included&rdquo; or &ldquo;stated&rdquo;
in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such
financial statements and schedules and other information that is incorporated by reference in the Registration Statement or the Prospectus,
as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this Agreement
to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy
filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing Prospectus (other than any Issuer
Free Writing Prospectuses that, pursuant to Rule&nbsp;433, are not required to be filed with the Commission) shall be deemed to include
the copy thereof filed with the Commission pursuant to EDGAR; and all references in this Agreement to &ldquo;supplements&rdquo; to the
Prospectus shall include, without limitation, any supplements, &ldquo;wrappers&rdquo; or similar materials prepared in connection with
any offering, sale or private placement of any Placement Shares by the Agents outside of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>signature page&nbsp;follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing correctly
sets forth the understanding between the Company and the Agents, please so indicate in the space provided below for that purpose, whereupon
this letter shall constitute a binding agreement between the Company and the Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%"><B>HELIUS MEDICAL TECHNOLOGIES,&nbsp;INC.</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Jeffery Mathiesen</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Jeffery Mathiesen</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">ACCEPTED as of the date first-above written.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%"><B>CLEAR STREET LLC</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">/s/ Ryan Gerety</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD>Ryan Gerety</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD>Investment Banking - Chief Operating Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%"><B>MAXIM GROUP LLC</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Ritesh M. Veera</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ritesh M. Veera</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Co-Head of Investment Banking</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Schedule 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Placement Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">FROM:</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt">HELIUS MEDICAL TECHNOLOGIES, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">TO:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CLEAR STREET LLC<BR>
 MAXIM GROUP LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Attention:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">[<FONT STYLE="font-family: Symbol">&middot;</FONT>]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Subject:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Placement Notice</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">[<FONT STYLE="font-family: Symbol">&middot;</FONT>]</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms and
subject to the conditions contained in the Sales Agreement between Helius Medical Technologies,&nbsp;Inc., a Delaware corporation (the
 &ldquo;<U>Company</U>&rdquo;), Clear Street LLC (&ldquo;<U>Clear Street</U>&rdquo;), and Maxim Group LLC (&ldquo;<U>Maxim</U>&rdquo; and
together with Clear Street, each an &ldquo;<U>Agent</U>&rdquo; and together, the &ldquo;<U>Agents</U>&rdquo;), dated September&nbsp;[<FONT STYLE="font-family: Symbol">&middot;</FONT>],
2025 (the &ldquo;<U>Sales Agreement</U>&rdquo;), the Company hereby requests that the Agents sell up to [<FONT STYLE="font-family: Symbol">&middot;</FONT>] shares of the Company&rsquo;s
common stock, $0.001 par value per share, at a minimum market price of $[<FONT STYLE="font-family: Symbol">&middot;</FONT>] per share, during the time period beginning at [<FONT STYLE="font-family: Symbol">&middot;</FONT>]:00
a.m.&nbsp;Eastern time on [<FONT STYLE="font-family: Symbol">&middot;</FONT>] and ending on [<FONT STYLE="font-family: Symbol">&middot;</FONT>]:00 p.m.&nbsp;Eastern time on [<FONT STYLE="font-family: Symbol">&middot;</FONT>].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">Sincerely,</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Schedule 2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company shall pay to the Agents, in cash,
upon each sale of Placement Shares pursuant to this Agreement, an amount equal to up to three percent (3%) of the gross proceeds from
each sale of Placement Shares with such amount to be determined in accordance with the terms of a side letter to be entered into by the
parties hereto in connection with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Schedule 3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Placement Notice Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>The Company</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Dane
Andreeff</FONT> *********</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Jeffrey
Mathiesen *********</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>The Agents</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ryan Gerety (*********), with a copy to *********</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;7.1(l)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Representation Date Certificate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Representation Date Certificate (this
 &ldquo;<U>Certificate</U>&rdquo;) is executed and delivered in connection with Section&nbsp;7(l)&nbsp;of the Sales Agreement (the
 &ldquo;<U>Agreement</U>&rdquo;), dated September 15, 2025, and entered into between Helius Medical Technologies,&nbsp;Inc., a
Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), Clear Street LLC (&ldquo;<U>Clear Street</U>&rdquo;), and Maxim Group LLC
(&ldquo;<U>Maxim</U>&rdquo; and together with Clear Street, each an &ldquo;<U>Agent</U>&rdquo; and together, the
 &ldquo;<U>Agents</U>&rdquo;). All capitalized terms used but not defined herein shall have the meanings given to such terms in the
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned, a duly appointed and authorized
officer of the Company, having made all necessary inquiries to establish the accuracy of the statements below and having been authorized
by the Company to execute this certificate, hereby certifies as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">As of the date of this Certificate: (i)&nbsp;the Registration Statement does not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein
not misleading; (ii)&nbsp;none of the Registration Statement, the Prospectus, or any Issuer Free Writing Prospectus contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading; and (iii)&nbsp;no event has occurred as a result of
which it is necessary to amend or supplement the Prospectus in order to make the statements therein not untrue or misleading.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Each of the representations and warranties of the Company contained in the Agreement were, when originally
made, and are, as of the date of this Certificate, true and correct in all material respects.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Each of the covenants required to be performed by the Company in the Agreement on or prior to the date
of the Agreement, this Representation Date, and each such other date as set forth in the Agreement, has been duly, timely and fully performed
in all material respects and each condition required to be complied with by the Company on or prior to the date of the Agreement, this
Representation Date, and each such other date as set forth in the Agreement or in the Waivers has been duly, timely and fully complied
with in all material respects.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">Subsequent to the date of the most recent financial statements in the Prospectus, there has been no Material
Adverse Effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">No stop order suspending the effectiveness of the Registration Statement or of any part thereof has been
issued, and no proceedings for that purpose have been instituted or are pending or threatened by any securities or other governmental
authority (including, without limitation, the Commission).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>signature page&nbsp;follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned has executed this Representation
Date Certificate as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">HELIUS MEDICAL TECHNOLOGIES,&nbsp;INC.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2526081d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 50%"><IMG SRC="tm2526081_ex5-1img001.jpg" ALT=""></TD>
  <TD STYLE="vertical-align: bottom; text-align: right; width: 50%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(313) 465-7000</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">September&nbsp;15, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Helius Medical Technologies,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">642 Newtown Yardley Road, Suite&nbsp;100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Newtown, Pennsylvania 18940</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Re:</I></B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Prospectus Supplement to Registration Statement on Form&nbsp;S-3 (File No.&nbsp;333-270433)</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have acted as special counsel to Helius Medical
Technologies,&nbsp;Inc., a Delaware corporation (the&nbsp;<B><I>&ldquo;Company&rdquo;</I></B>), in connection with the sale by the Company
through Clear Street LLC and Maxim Group LLC, as sales agents (the &ldquo;<B><I>Sales Agents</I></B>&rdquo;), from time to time of up
to $92,800,000 of shares (the &ldquo;<B><I>Shares</I></B>&rdquo;) of Class&nbsp;A Common Stock of the Company, $0.001 par value per share
(the &ldquo;<B><I>Common Stock</I></B>&rdquo;) pursuant to (i)&nbsp;a registration statement on Form&nbsp;S-3&nbsp;under the Securities
Act of 1933, as amended (the &ldquo;<B><I>Act</I></B>&rdquo;), filed with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;)
on March&nbsp;10, 2023 and amended on May&nbsp;25, 2023 (as so filed and as amended, the &ldquo;<B><I>Registration Statement</I></B>&rdquo;),
(ii)&nbsp;the base prospectus included in the Registration Statement (the &ldquo;<B><I>Base Prospectus</I></B>&rdquo;), (iii)&nbsp;the
prospectus supplement dated as of September&nbsp;15, 2025 (collectively, together with the Base Prospectus and any further supplements
or amendments thereto, the &ldquo;<B><I>Prospectus</I></B>&rdquo;), and (iv)&nbsp;that certain Sales Agreement, dated as of September&nbsp;15,
2025, by and among the Company and the Sales Agents (the &ldquo;<B><I>Sales Agreement</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In so acting, we have considered such matters of
law and of fact, and relied upon, without independent investigation such documents, records, certificates and other information furnished
to us as we have deemed appropriate as a basis for our opinions set forth below. In conducting such review, we have assumed, without independent
investigation, the genuineness and authenticity of all signatures on original documents, the legal capacity of all natural persons or
entities (other than the Company), the authenticity and completeness of all documents submitted to us as originals, the conformity to
authentic original documents of all documents submitted to us as copies, and the accuracy of all statements in certificates of public
officials and officers of the Company that we reviewed. In rendering these opinions, we have assumed that the Shares will be offered in
the manner and on the terms identified or referred to in the Registration Statement, the Prospectus, and the Sales Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The law covered by the opinions expressed in this
opinion letter is limited to the General Corporation Law of the State of Delaware as currently in effect (the&nbsp;<B><I>&ldquo;DGCL&rdquo;</I></B>).
We express no opinion as to any other laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on the foregoing and upon our examination
of such documents and other matters as we deem relevant, we are of the opinion that the Shares have been duly authorized by the Company
and, when issued, sold, and delivered by the Company in accordance with, and as described in, the Registration Statement and the Prospectus
and in the manner set forth in the Sales Agreement, against payment therefor in&nbsp;excess&nbsp;of&nbsp;par&nbsp;value, will be validly
issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In rendering the foregoing opinions, we have assumed
that (i)&nbsp;the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL, (ii)&nbsp;upon
the issuance of any of the Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number
of shares of Common Stock that the Company is then authorized to issue under the Company&rsquo;s Certificate of Incorporation, as amended
(the <B><I>&ldquo;Certificate of Incorporation</I></B>&rdquo;) and (iii)&nbsp;certain terms of the Shares to be issued by the Company
from time to time will be authorized and approved by the board of directors of the Company or one or more committees thereof established
by the board of directors of the Company with the authority to issue and sell Shares pursuant to the Sales Agreement in accordance with
the DGCL, the Certificate of Incorporation, the bylaws of the Company and certain resolutions of the board of directors of the Company
and one or more committees thereof prior to issuance thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Honigman LLP &bull; 650 Trade Centre Way &bull;
Suite&nbsp;200 &bull; Kalamazoo, Michigan 49002-0402</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Helius Medical Technologies,&nbsp;Inc.<BR>
September&nbsp;15, 2025<BR>
Page&nbsp;2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We hereby consent to the filing of this opinion
letter with the Commission as&nbsp;<U>Exhibit&nbsp;5.1</U>&nbsp;to the Company&rsquo;s Current Report on Form&nbsp;8-K, which is incorporated
by reference in the Registration Statement, and to the reference to our firm under the caption &ldquo;Legal Matters&rdquo; in the Registration
Statement and the Prospectus. In giving such consent, we do not admit that we are within the category of persons whose consent is required
by Section&nbsp;7 of the Act or the rules&nbsp;and regulations promulgated thereunder by the Commission. The opinions in this opinion
letter are expressed as of the date hereof, and we disclaim any undertaking to advise you of any subsequent changes in the facts stated
or assumed herein or of any subsequent changes in applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Honigman LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PDT/MJR/NDS/GDP/SEM/JPK/JHC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>hsdt-20250915.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaaJubOdzZR+aYkxtmB/bdlKjykpPxgRSSqVoPnW4aMH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:hsdt="http://heliusmedical.com/20250915" elementFormDefault="qualified" targetNamespace="http://heliusmedical.com/20250915">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://heliusmedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="hsdt-20250915_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="hsdt-20250915_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>hsdt-20250915_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>hsdt-20250915_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="hsdt-20250915.xsd#Cover" roleURI="http://heliusmedical.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://heliusmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2526081_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2526081_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  E -0# 2(  A$! Q$!_\0
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M?AS^%>OZBP.EW9S_ ,L7Y_ UY5XQ\*:MJ'C;2_$/AV*PMIK)AYC/<A?. /3
M'<9'XUV^KZAJT_AV:.SM++^T9HFCP]T-B$C&<XY'M0!R?C_X</K]C!KNAN;;
M7K51(CQ_+YN.Q_VJ@\)_$4^(]%DT764$&NVK(LD<G EPPY'O[5W7AZ^OSI\4
M.KQVL-PB .\-P&5C["N6\8_#_3]9US3=?TRZAMM2M;J*24JX F0,"V??% 'I
M,?\ JU^@Z4[=SBJZW4'EX2:-G5<X5@:Q='UR[U&XNHIX%0(^$ZY(H Z2BBB@
M"K)I]I.XDGMXI9!T9D!J(:+I@Z6,'_? HHH 7^QM-_Y\8/\ O@4?V-IO_/C!
M_P!\"BB@ _L;3?\ GQ@_[X%']C:;_P ^,'_? HHH /[&TW_GQ@_[X%']C:;_
M ,^,'_? HHH /[&TW_GQ@_[X%']C:=_SY0?]^Q110 ?V-IO>R@_[]BC^QM-_
MY\8/^^!110 ?V-IO_/C!_P!\"C^QM-_Y\8/^^!110 ?V-IO_ #XP?]\"C^Q]
M._Y\K?\ []BBB@ _L;3?^?&#_O@4?V-IO_/C!_WP*** $_L;3O\ GR@_[]BC
M^QM.[V5O_P!^Q110 O\ 8VF_\^,'_? H_L;3?^?&#_O@444 ']C:;_SXP?\
M? H_L;3?^?&#_O@444 /ATRSMY?,AMH4.,?*@%3I!'&24103U(%%% $E%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 15, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 15,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HELIUS MEDICAL TECHNOLOGIES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4787690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">642 Newtown Yardley Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
    100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newtown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">18940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">944-6100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class&#160;A
    Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HSDT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2526081d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://heliusmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>hsdt-20250915.xsd</File>
    <File>hsdt-20250915_lab.xml</File>
    <File>hsdt-20250915_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2526081d1_8k.htm">tm2526081d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2526081d1_8k.htm": {
   "nsprefix": "hsdt",
   "nsuri": "http://heliusmedical.com/20250915",
   "dts": {
    "schema": {
     "local": [
      "hsdt-20250915.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "hsdt-20250915_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hsdt-20250915_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2526081d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://heliusmedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2526081d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2526081d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-25-089778-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-089778-xbrl.zip
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M'Q; 6-HCC*,I>(CE(!7--Q; 4J@R4!N70;9ZB4"NA&9;"X2QG,M_#)3$,H2
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M&PA()??+R%)@EB9J .N%I"UU?KH!F&V=>ABZH#@!S,&G))7>+RF+1T*INAV
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MWE;V#CFT--ED[-B,V"(BS$E,@/^FCVS(4)=14"Z=(1D."%)G69TK@3JC&6]
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M^-RR]:NQW/W1I5RGMU*+R!EU;YA'3D^;]W'PE:TN1B%OQ\:K '!=84XTL>
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M.TDE-\,N'0_1?7-.-.ISL8!B\.#VO6 UD@,23-1M<>EQP,;4'(9+V:+4'S3
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M3$G1MN4_UU5+CT -TF;X8GCXBZ9=\FS>WWL(8EM/%^L9O!C^"6L#"PIZ?;*
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M-]2JJMFQHW@*BF>V ',9G?K0G'6+?57 XV;9D0IA)DAV-=QCR<O#N"0^YO!
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M2&GYB#^'Y<6IS$8B_W")B:]Q> "V#PY#O$'1$OKC9/@CCQP;1M"I>R/W\RA
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M]\>(!@Z&L64<<"44_J)T<>9?:Z+@(*GH;!^SOYV=O0W[GJ&BYC+MPE0Q@ ]
M@/XC1NV'V%^.Y<WP\"P5R&6&0]6/13OC33"5#@RX1AF:>4/2 X-D['2#P7JM
MZV(]JWJ.V* H+9-G*%<C#4ZPP_,D#YN24JK1/&^:G@7:.6]PSG"%.+2RD4XO
M,P1/X9E$$W.Y1.O8/#6JK1BL#=O SGLB1DP^&+F:_+YH?K$1%%9O00W'MIN9
MB"4NRF6SN"QG3S@F1T_R\Z8SBCDS4'#8N&^&[,5Q3;L5>U^L=EWELR7^FUU?
M^5"X%8.?S"Q!%#:D6%3/R$%TQX\DEZ25^C[$93AI6< G3)KF8R?%-EAL%:OC
M)RRD(K3IYQQ=P.N:EI:8XLP-H4N+8XIZ)J/[MZ+DAY%_]SHCXBRTXR\QI4-/
M F%P/=\<%Z+3YEJS1<D 6[5%3FHKE!C,*R1H0)^3EC#SO4FQ(&4)3E;9VV<<
MY\)HN"4#8H)1J)Y,!QR?ZV"K_C@5O9.>C)1MX*#P&F/5-Y?_+43H>XL_[)+(
MOV=*$JV-==VDE+P +LN"!JT)PB/ET:!6AY5)J#,@9 L1WR [>(RG*)4 BSP$
M3Y"5_4V?$C@R^*:7"!0_/9$.<OK]]_?^8XLC$ZASV*L_@B=Q2U9EN=N'IKP3
MV-I8=6E(C[W(#8J/)&)A@A1[,[<F@$NHUX*TF18:53A+TH/R7F0TM2)FQCBE
MW+$J1"$)ZOL@X*+>\YQ3D'@@D)Q(\FY:3!C>_0%37"!P'^Z^\,P'PO/&5"F1
MK#!ML\DR$;Q+BIDPW7D)@YC!1XZBCI#\MI^O&*A44^&:,OK#C,2?N.&HA'^#
M8]V!Y:XFOBV:&@S%!.@Q<D$#@W.OIE>&96QBA>.0T*&%Y0J&1H:[J?Z"5T[6
M'>A!8=Y-#YN=$ATW\U"1+14,O_*DF?"]*[#&NXMJA0-;E&*OPMT/\M<[OC&T
M'-=<$X8_<D/13E2LL66.=%'+')7 1X$=5 :CUQ$X35>"_!187K\)P[8P.AP"
M51[@BV5<VB*1NA?QR()A%4'A__9K-Y4#*J,F7*[F0Q(BC=E"MG'#S6B$9IO;
M!=$D<4W\)!F/*]G8[09S+G:+O[N*&:HCC:0)*H 9O-1X*+JN1'="5R2WKB4X
MBT6+8!?R=W5!<P]CRH[\]6SY$(YSU_L(>X\-W=!,O= V[=5&1BG%+P7 PVX*
MSY#N:_@GVBFLU=$61G?%>MCC@"[!SP1$_;_HZIW)ZCVG!?N#]"JY);5Z/JS-
M7D^Z:E85;24EC:$N@_/7B26LTJG_Q6UU9"]DWVG7RJYW:K,SCZ=Z-XYE4.-R
M01:#QPYS!UNK/:<";C*@-N(GP[/@--;3]7)"3 XYES;A;[E<&XS9=6?$%.6N
M;UG1Y0Z)L_<0T>?0>\,VO*6@^!H%$^GD<^(G*HBYR%4TT>Q(=8(QL6+F.?1;
MD3P09LLE67=?Q"Z26(;_4S5BOL!&/>,"I2%44Z B1R:(<NE_R-N%@M)+:G%S
MCZ^ZUJVRO98+@\!Z$H1F$"Q)0U"X=\8J""\HPBJUCL*.M$_MNAPLBA5?D(15
ME_1FKOVQ&P$.BN(O,O<:4>HS;EU.7C5(,U>43[JRO53R&ZIA+;&6&]ORU46M
M'JAHYK!M(H59<6O@;LJS9=/VYU1O-\,R#QPEUL;FV:+!^DUGY;JS4GA@L\ >
M6\XW.BA2!.0IA#F1RV637YDT:R;D=<\P+)[6K. K:G C5)V2"S&;<E6-20,I
MC^**MI\!BYH@^VT].]?0P@RKX%L'F*2;R=G2\I1ILVZYWT$+'G>+9?&T(G'E
MO"F:=U>Y&@MNCS7DIRR@TP56671!97\099.6!4KJ0J+C)DKCT(I%TXM]3]/!
MU5%2_ ]K)Z?BF8A1,7(MPKD,(FI:?G%XX(AX<B)8Z2V=IG(K.TM%$:,)D?/R
MP?R;*EI,"Z<S%B%W83[')HH,L&@=!!6=O#0WGO.7JYOW2^X]_I;<^Y;<B^_C
M*HTM'+>&B8=?6],ZMEY/"$%9&,YJ*;F!1YO Z67*A]\]KV>*Q8,6E,*GOQ-Q
MS75#;>FPS)@'.SPXLO0K(ZN4;V%I<4V^G Z,FS!8S1_VY4'[0DG$P$G;$8#.
M]HD_:WU\3-6PSS O_2@-M$*"HNZR6U4]91&P%P)J^77OO.!%4Y_?XR@NR.L$
M=H*<<\NQX(M/+[#<M1"HE[ <H*][1<DWOEO8A*<D ,;G+HFY$V/UKLC49$GQ
MB;ZGAQV7[4E )IG,'0U^M<,ZY;_# I=/R);&E9*P%1(+)+"8;V"OW_)5K?KE
MOII0YWAX2_!F.R0+SU/HM2MBE;HV92]#F\(NNT.M^;U[YKM46.X*&QL=0NG1
MVGKN?\CTJ\00!^=(NN,6=0WVW;2<'?/W QDA8\2W8[#P?1+6CQ42/TB94LZ-
MN<CKGY6Z )$\A<EL(S?:)8V,+3*@=,L;S#<42 R#5ATOEXL+D=EIF!0^MS!Q
M']6#$.%8]WS!IL8M73N_#:/_O+7#$*XINK9'0DY@+.VQ4'@,0^BWYY'/+IY>
M[+;G05W']6I5!P@^25@:<E1B_O(! 0X"Y,K/DHAB'!Y$ 8-!W0T.T]4PYV.K
M-PU6.XO[]^R.AQX>V-1?!&(AB?9I&6[<;([GF#9O5I)<U2@-<AO1KJ[KRM:5
M2; FY$2A)P;M ^/B<!?J%U%9<6LFOB10(>]S/7C!"]5UY*CN<7%P-B=U>61;
M[XX\=7GDH[<'T5Y$UP<#MCD,80KC@Y,DP!Q73<<A\Y6%^EY':J1$RTD-BZY]
MJ%Y!?N(#S-CU(O5HP4CI&$?;%&Q!0?]DPM?641F6R?VF.9H3CP51N,LYU\>\
M))+LBVK,$R<IK-H*T0M63NE*7#E65;4/<HV"J))I714\L_V"=4^9$2=I%'4P
M>Q( (1)RV&#;)SY*@<0J\L;5B#*M@H-5<<=CTG$EDMT)NWI:R[>.:E,'=C\[
M2ZCG?2K?J*Z,B<S@<FXIR44J3MX>TI&XTSRN9WQW"CKS_L;';."=O]L_#N[V
M,U$QM !/#@^>HV*9EN++# .]>(_AU2SD7B2I>3(;B.UT:N[SD2 :J6<:3MV>
M$6(N\LD&1Q'5R2H7>,@-HE2:<K-Z'$+D1U$J%HULFHCDG!F05<DI]6'7>=BN
MM=1%6GC>U$@9QL39! ="XFR7HO0<I@%X@"*%9; +"@*4EF9$L#(IZH_M>M5/
M">G:(02OGA)NQP;2*;*,8<]JO;3!=@J^^[PC4TLV/ADH"LC@/6M:0/F +WGN
MNFE0GR'!&EVO()K+VB63I6"X]O[%MB[")W(A1M/'<6B#3PD@HS[P6I GAP+&
MJGS5P/_=,*IT5@I4-HA+?@V%,8OM1W\+4^J'!!9':QV]">L/6KK3;['"O?;G
M<,@&)+=KT#%M#QJF(6,K_6'.'J.C.M4;6H%"_%P8N#H?YAVL&WP.<:LODH]D
M1U<2:^<L:9 )U52I2VD:+D&F7PS]5$Z2$&>JQ)1:[KR6]%!*"A3L=ECTF@Z\
ME@  8XE,1UF03Q^X,(8%WNTA-]L+=#W0;T\C5U)AQJB0FR<P;>_\05\FP\9/
MN>*S _.8D;9\ME\W6@N:RPG%N["PFL&GXJQA[;%04Y>0:Y2 +IV8(_MQG\0<
M&LPH^B%RZS*TZ(C<?2S;*7[\,?[;X9ZUHL)1;>>N<]G&&B1:"1L$L-)M0IS!
MZ2CP4K]+'0-3T,!M-&0;.K\/7;01G>R$@L7];G2#[>@,Z7'4EL$PV'+U;71U
MTC%2)2UY>GIAT",;_^IJC<"4GX&XM@[MB-MYYK;3%'Z\>/GZW5E0^1$7'P;
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M1CQ@27IX]-#EH]@??J[/>E?VHK>HH^K2I:6,]_C#H]![--E(G8Q']C,U4N>
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M'LFQ9<C3YZ]S2N7Q"R-&?',)=\<&48.O0I.1[!:Y[G.G2%4U..T+.I2E[O"
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M;X/#@S><]N20V=&I?&UW[.SH@7PU&40S %0?1!N[\>/#*^613&NAEGE<Z.7
MU,I/A8.JJ04=!E\Z,+[)[M4$[MPU<^"ZL"@,?62Z'NAHGO)7PX!ZX]M'\X.X
MK*&84O.." +##"%+3C^!"J=,^^ 78[5K9&((#BQG>!\\$ UKMT\6Z+MEF0>A
M\N'55;G<&:^U+R]/7G_6EL%[TMDB<G54$:/\P/+:;Y-'-U0)M58,=.6M^+SE
MWM=DB&S<PX-1(W=4XG\_&S=DS]PCY3FZPD]&21TKA#R6:Y>7V+));/8Y0A_7
MNTV1@NF@3.X.%Q7O#5TVN<OE;!^%/J&TF7I%?PP;UVOEFF:3@VH_R8 S06@A
M:.-QC>(1_>-$>ZIU'8I]Z<OFL.W9G$AJ,$$TM#IH:76&S.\H)JNG2%$_<M=8
M$TTBF,[*+<F64MPHC(RETB-,,86K9;2F4[0C7S+7Q"U=MO40=-4L,<=Z>."E
M\K-NVYM< GEP"]#.7^<:L#U0/B\081,_:>\AP5'EGT1A8+B)/^/:8;CVK&00
MF^LWQ1T?3(&L40Y\DKI!4U[>6)'M+K05^% W9G=MC:[Y75 A)"Z[6D/+LNPE
M)&B(RWP+%J4DCM:IOL6@#2BK_[$+[3K>W7!ATVL@UUEXIP_!/3&&;(NQ6L0;
MNMVP4: %K-O1Z<F(S6Q5 L<Z2L,8Z>FV@GJBEBM_;5,UEIV K2L%$$LU/'?@
M&SLUQ]86/0&1=,DCY:\?HB;?PT2S:^Z"PM.FGE<87SUWQVB3<?L#>YBQ)2]H
ML*EM(H>_L^@63+<:*L@(A^,N/7Z.BK.)DK]QC4=_;K"[:-R8X^G9FY\#57!X
MX%./N+Q</^&A'3/G"\$LB3]7&<GG%1U!_U4WEP%K=C+SX9N=2?<FHAF%K[;5
M8A.4SOD-4]X#F=%4]E]4H.9(X+5D^: CAJ<\ 87SW;8SV13-W<,PCGC0;==;
M6X=7P:_E2R)N741"&$3Y!>"CZ[M>S225 @]*_]S#20.*3P,=M@T1B?C.E4F/
M//&B(.HX^LDY$N$&^#2&?8+I2\U?BHA?+F!;QQMQ3ULLM\88GRACC07UJ8$]
M>2<LL%]_.FJT,.BB*DT^Z_#@#>-EG6X;8(->[J?OG8G5W"@> C)^_8#([;GJ
M@^ F^V/7MIGH+(QULPL-0]<#4(%[X<YDLC%Q6RT+EI:C;YKHBOY1O1,OD&9%
MO?Z#;2H&Y]8>&^W%S@@BKX#W"R#8W&%D#;YX,Y9"NRMG;B4"#7<FF/N@P/SU
M/SAE_P/A1.X(]/L<GVMZ'&HA?L;Q<8L\X)Y4"<[V$& 8R-X2/-C6.RW/6[WX
M?PZ\^%\(<TO !VF\/%*WLI6\PZ,<B%Z86BJ3O-G.]>Q6$!"8R'LK9K,G"X6*
M.*L>!*5C*#!9HN8^FS#=V50;Y;KOLWQB,]QJ4?W+U4W!@E:KM>_YS'"ERM#3
M*P-15+^,KG(QQ4)1CB5=*%,#C5LJS8-29:[H54N8N TF%:6_:7Y1);G6-T<]
MJ=\Y<'3VRQ@RA1^'I2/U!J,E!?5J]!ASSD@W<'"Y\%C?/$['%<%+^?Q\P<=@
MOSS@@V]YP*\I#]@.E-I+0U+@7=TQKC(IKV.,PWQ>5*V/0B/Z$?R_UG,]&YT$
MYXY:.G$G>\MG :>R#,I,D?O><+]LY?8@,C*YO@RAPU3N2;49D3$-AXC/XF#;
M7(%8[-.Y7YHE^(+/]BU)0Y<@M"+OB2-8[T$_2RV%"=G6.[I9H#T$UCROKG8V
MBRDAQ)<5(T2H,Z;%"FZ3GNE8Z2_<;DR*^.JRDF&X']821W1I7-.:M=>'T-NB
MLL^@+ZD?A20$S3A0;(Z%$@B)^G(D5,NU]6;N.Z#G.F^^_60)Z> XVJ_E<ETK
MH/.H",30U'>=/![O 9MS8>:@\4.R\V=L+;CB"4L?)'>@.U_V.Y/U,"+KL5UW
M_WST@_/QOF@G15UV]]Y\6I0;LC1&61TK@GN2]'TLRQ5&V-94SCMIFH\JE0C0
M)4#L @-G*K==5XK<NL<0MSR2$YFX)C%%-0LN8G;JU]J1&BHW9=,^.]B6YT5K
M8L2^KR)!>=6=9A";=(H4XQ"EWXG,W$=>3')R3A0L,FBE+4FADO]V=O96N%Q]
MS!IYK%8DFF6G+0:GY6RM=<'>C%Z)_]]KDWI<J9H=GV;NEEA3U[: '#R=:N'V
M9<%Z"2\U"@K1EO 59&O!A?8&IE.Y^CS\DFQ:[*EY<]>!39.;P3'MX$5M*:-/
MQ Q7>"OVJ=U(!?=1":!)1EYC>KM&-B8/6ZD6TB=J)>))M,HS4"]M&4^=QC\I
M<3NI,1R#IX=O\9$>'TJ(6C.Z>2C_DPM1J_HMN.8^;&NXI_!+8R[E@P.M(F!N
MX=6"::UKI^=GEAJ(;@/FE7(",;8'(A^BE%V0V=2,*,\2WX;)A,SAP4#1X CV
M()UWBD0;9Y+F,/D!?\!V4AO0\30W$=SNKI70PY,']-"_G'SO\BN!TI2.2K+#
MIGC:UKSV'D%L^*2]7C/F)"H_V_4K;.SN^*E2G5Q+UX%)[5)&\#)JA5B]1LJ&
MJ(4\'\U<.=[AGU@HO(2;B.6$S0YX/B5U??K)]($$ P.L)DX+5'5T@_MVC+XV
MF#04S';G)B&SN=ECHSY'UC'['9?Q\&!\'5']+M=,K8$C]6:2CY;%9\GK#)OI
M)/XWQW/!P31J"<]19R9W]%_P!TR^P#&#LNU0 N%_<3FH^A16%=DVYNM:>UX6
M8N;"TR1U4R#DVFN/J7 ;>S7CEM17!XFB"[?!J8-!,[L$=0;5C("*0XZ<F@FC
M<8OH1'=6YGRDO8"[?(KL(3C.-1?2TC4B_8^"&G:'V'*MRIQ2%Q-X]@<W T_V
MJ%#[,^A=;P.^+3::2'_.707&XH 4?UHLM/D M0>H9K8HD(5,V=M0@"V#2:IO
M<8[Z3B7^R#8Y-W9 +@@[>SJH0 '9,V+F >LRL*JHV+S<VA,!4]KNV:F[2NP#
MP@%UQQ2K;JMSY-=T)9 %<X]'?8;#3"9?!7V3NSB#L#8PXX<CT^5@.P+<O*%D
MK2\):M;.D)UI^X.(<S"9G^"NY;VE@.H29 ZC;$*:]\Y=H#&G4&D>D'.Z(8W$
M(/.XKWVPY>Y)I.?B9YD\0T>8'](&VI(EU8?&9D)#,>HTEBM.-%JMY#(6GTK?
MS5"H"V$H:_1?L0Z^6*XR_B]#J>7^FW^NW!^.)?3ZZS3$D)A.UX<'= K$C)^L
MVT[D51>*L:=Y &'Q9A(QFS5M3&0"+['=M&VKY'5_KYG?6\&2E;U7!5C0.5S=
M\:%%P'61UO4*/_BW'Q[GH*CNGYQHO950M?"A<+W[L  R^0*?"-77!/3PKASR
MDTQQ4L)E=RP6CINIK\*^WNA/=?1P.R.R/BH1PZ6]P2GVE"X$+"-_"4V*'=&K
M(PG*'!Z8288)9"?AIH5+Q&XA2BNML[+M*NO2'G$T6,P9O_;<\?/) MLU?<0R
MLO:RW+CA/P4K:E;Y .I5"S8-PB8D:"I?,_,B2V&+-MX],[N13A;-H?#^-BH4
M"N")F/$E1$UZ'<K=\+EZX4P_VEZ]7/)&?'%P![YX^?K=F662=N/0%%9:%YMV
M.>80)">5%']Q5W<.>]T.NUBYBV7!#<UDE(F&8E$/L2_86MLO8?7P6\+JSB2L
M]K&]_Q+8WD^;>E8YXO&0^^^-MYR]/6[-Z2:HW/<1AAA19/'*9,=/2N4!=P43
M4D--JICBA].->J^@+/N26!GEA6V *^$#+L3;52D.7.17:^];!?&M0U]AL@D+
M?1*^@TF<N"'3T%!]3 :DC6DVS1@X4O6:J_$:[_! .Z2Z1MC1 KFG,!5'J]B9
M<!0N_8)D3^0DMS18QYINJII]C_:I$X@_.B?7[G1$,4A'C+$_/5<:*G\01E"E
M!J/$J=C,4%@YUDPDWG!LI>HS;&O*P=$G1YG*422A-9]LDFU2ON";Z9;V;Y),
MM_ZB\1Y>!M%=KXE )19\"E1W=M.D,H!\Z>^H$8(Y>7_U 0*)VL=Z1JQC0< R
M0-2<KF27=D."*0P)[!G-RQDUPB0^?(R*G2.ZO,8MQK05!]#[3:(!#\8 5.I0
M<3I\Z+9VC*BPL9&21_DQ=%O)ZG%@8YQL0WM]6QD<H:Q"%^!)%%EPWND@IG*S
M-5+@%1@/&=DLVAG'A>N"!=L>JM%JFXJ@ZS[1N^&H<,D%!G/%ETFN[HD--J3%
MAYGO:B$"ULQVJCC!]MSAH0:=8Z5=PW+E)2WZ.[]GQ!:70M-B4:;ZK*:FCY_
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M3?J#&%IYH@#QX&>V>#<,@PFQ<%:LG6-*!$Y=,!O+X+>L:? ;_SFTZ ^&&J;
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M\Y_G+"9P7,J><8></Z_N[KN!;ZH3Z_+S"K(!%+3K%%W"T!B-@.D% PK*,05
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MF&J*$[[&A4SDY;1J4.%3\#67\YD".[L@TNVDP-QBV60)@0OD[TQ'JYQ8N%Q
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M2X8ED#<7":43L[9S*DR6 $*4BCI+X$PO<LS@'8*28.N@N)"JP4I)A7PQS/-
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MC^\_;?BG#T>[7U K?AH<[,L?_A]02P,$%     @ 6$8O6Z8ON 1U"P  1RP
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M]M2 :N]+9P9V#^+4+]?@ FW7QC*9E0:S@,=VM9^M^O8,ZLKMU/P0M4T;</+
MCL>>K4SDO#AE\R&W0WBH[>S)0S3IXE2&]GX4::^*IHB)3NSLFQ]\W4YU*HKD
MR30?OUUL!NYME(OCK_F,8%]Q.$<3-"J?-G>B.<DB[D8-#&RS+)K8:=W.!2X\
MRQ'0YWV7#<LG%/Y<8@,QY,OR]((7 PN=8#,W=K@443!D&D1<SNR@;]4:_M'N
M8C0B-)?P>*&S?">09J/4TJ]A[NU*FN>&CFI3=UX6NK-Y?VY%^J2R,^9#,DJ;
M&PQISS@5_<"_BRC]3.K!'SRX7W$]V6\%_A*H Y/0>0>@D*3U[>_T'^O45@_*
M%Y]*Y--%H#R1/?</&IZA^U[WALVKWV^:[WN#YD7ONCDXOVK^?OU'\_=W9]]O
M$WW<"-@^9A]L_TB/6)^GYON9"+_=>-:D'P*[7P;3#XC_"U!+ 0(4 Q0    (
M %A&+ULJ/QEI*@,  /$+   1              "  0    !H<V1T+3(P,C4P
M.3$U+GAS9%!+ 0(4 Q0    ( %A&+UM\HT[ _0H  '^&   5
M  "  5D#  !H<V1T+3(P,C4P.3$U7VQA8BYX;6Q02P$"% ,4    " !81B];
M7_BVP5P'  #>5P  %0              @ &)#@  :'-D="TR,#(U,#DQ-5]P
M<F4N>&UL4$L! A0#%     @ 6$8O6_1/9U][&0  .X8  !(
M ( !&!8  '1M,C4R-C X,60Q7SAK+FAT;5!+ 0(4 Q0    ( %A&+UM?RX-N
MVZ@   AU P 5              "  <,O  !T;3(U,C8P.#%D,5]E>#$M,2YH
M=&U02P$"% ,4    " !81B];IB^X!'4+  !'+   %0              @ '1
MV   =&TR-3(V,#@Q9#%?97@U+3$N:'1M4$L%!@     &  8 BP$  'GD
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm2526081d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hsdt-20250915.xsd" xlink:type="simple"/>
    <context id="AsOf2025-09-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610853</identifier>
        </entity>
        <period>
            <startDate>2025-09-15</startDate>
            <endDate>2025-09-15</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-09-15" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-09-15" id="Fact000004">0001610853</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-09-15" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-09-15" id="Fact000010">2025-09-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-09-15" id="Fact000011">HELIUS MEDICAL TECHNOLOGIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-09-15" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-09-15" id="Fact000013">001-38445</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-09-15" id="Fact000014">36-4787690</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-09-15" id="Fact000015">642 Newtown Yardley Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-09-15" id="Fact000016">Suite     100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-09-15" id="Fact000017">Newtown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-09-15" id="Fact000018">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-09-15" id="Fact000019">18940</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-09-15" id="Fact000020">215</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-09-15" id="Fact000021">944-6100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-09-15" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-09-15" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-09-15" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-09-15" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-09-15" id="Fact000026">Class&#160;A     Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-09-15" id="Fact000027">HSDT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-09-15" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-09-15" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
